
<link rel="stylesheet" href="https://bootswatch.com/4/flatly/bootstrap.min.css"><link rel="stylesheet" href="style.css"><script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.16.0/umd/popper.min.js"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1">
<div class="header"><div class="top_text"><p id="home">02/28/23</p><p class="summary"><strong> <em>Summary: New data in 1 study; Expedited timeline in 15 studies; 17 new studies; 1 new approval.</em> </strong></p></div><div id="images" class="logos"><img src="data:image/png;base64,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" alt="Lexidyne Logo" width="150" class="lex"><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><img src="data:image/png;base64,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" alt="Janssen Logo" width="150" class="jj"> </div></div><h1>Clinical Trials Weekly Digest</h1><br>

<h4><a href="#clinical">Clinical Results Press Releases</a></h4>
<h4><a href="#new_lc">Lung Cancer</a></h4>
<h4><a href="#new_it">Intratumoral</a></h4>
<h4><a href="#new_ct">Cytotoxic</a></h4>
<h4><a href="#new_ia">Immune Activation</a></h4>
<h4><a href="#approvals">Drug Approvals / Applications</a></h4>

<form action="https://getform.io/f/387eb37d-4992-430e-99b3-0bd1f47d1fb2"method="POST" id="interest_form" enctype="multipart/form-data" name="interest_form"><div class="form-group"><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ###### CLINICAL RESULTS ####### -->
<!-- ############################### -->
<!-- ############################### -->

<h2 id="clinical">Clinical Results Press Releases</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Elpiscience</td>
    <td>Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF- Bispecific Antibody ES014</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05381935" target="_blank">NCT05381935</a></td><td><select class="form-select" id="select_form_1" name="NCT05381935"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Nexcella</td>
    <td>Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04720313" target="_blank">NEXICART-1 (NCT04720313)</a></td><td><select class="form-select" id="select_form_2" name="NCT04720313"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>IMUNON and</td>
    <td>IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05739981" target="_blank">NCT05739981</a></td><td><select class="form-select" id="select_form_3" name="NCT05739981"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Accutar Biotechnology</td>
    <td>Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05673109" target="_blank">NCT05673109</a></td><td><select class="form-select" id="select_form_4" name="NCT05673109"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Priothera</td>
    <td>Priothera cleared to begin Japanese arm of pivotal Phase 3 study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05429632" target="_blank">MO-TRANS (NCT05429632)</a></td><td><select class="form-select" id="select_form_5" name="NCT05429632"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Actinium Pharmaceuticals</td>
    <td>Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL Webinar</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02665065" target="_blank">SIERRA (NCT02665065)</a></td><td><select class="form-select" id="select_form_6" name="NCT02665065"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo1" class="accordion-toggle">    <td>Fore</td>
    <td>Fore begins subject dosing in solid and brain tumour therapy trial</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02428712" target="_blank">NCT02428712</a></td><td><select class="form-select" id="select_form_7" name="NCT02428712"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>

<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW LC ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_lc">New Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Solid tumors including colorectal cancer (CRC) pancreatic cancer (PANC) non-small cell lung cancer (NSCLC) and other solid tumors that express CEA and have lost HLA-A*02 expression</td>
    <td>A2 Biotherapeutics Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_1">Study Arms</button></td>
    <td>A2B530; xT-Onco with HLA-LOH Assay</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05736731" target="_blank">NCT05736731</a></td><td><select class="form-select" id="select_form_8" name="NCT05736731"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced solid tumor malignancy harboring a KRAS G12D mutation</td>
    <td>Mirati Therapeutics Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_2">Study Arms</button></td>
    <td>MRTX1133</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05737706" target="_blank">NCT05737706</a></td><td><select class="form-select" id="select_form_9" name="NCT05737706"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Advanced unresectable metastatic or recurrent melanoma and NSCLC</td>
    <td>Biocad</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_3">Study Arms</button></td>
    <td>BCD-201; Keytruda</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05739006" target="_blank">NCT05739006</a></td><td><select class="form-select" id="select_form_10" name="NCT05739006"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced or metastatic non-small cell lung Cancer</td>
    <td>Shandong New Time Pharmaceutical Co. LTD</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_4">Study Arms</button></td>
    <td><p>F520; Pemetrexed; Carboplatin; Paclitaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_503">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05741021" target="_blank">NCT05741021</a></td><td><select class="form-select" id="select_form_11" name="NCT05741021"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Untreated resectable early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC)</td>
    <td>Innate Pharma</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_5">Study Arms</button></td>
    <td><p>IPH5201 + durvalumab + standard chemotherapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05742607" target="_blank">NCT05742607</a></td><td><select class="form-select" id="select_form_12" name="NCT05742607"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Local advanced or metastatic non-small cell lung cancer with HER2 mutation</td>
    <td>RemeGen Co. Ltd.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_6">Study Arms</button></td>
    <td>RC48-ADC; Pyrotinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05745740" target="_blank">NCT05745740</a></td><td><select class="form-select" id="select_form_13" name="NCT05745740"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Lung Cancer</td>
    <td>Second Affiliated Hospital School of Medicine Zhejiang University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_7">Study Arms</button></td>
    <td>Centipeda minima+PD-1/PD-L1 inhibitor; PD-1/PD-L1 inhibitor</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05735028" target="_blank">NCT05735028</a></td><td><select class="form-select" id="select_form_14" name="NCT05735028"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced non-squamous non-small cell lung cancer</td>
    <td>Xiaorong Dong</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_8">Study Arms</button></td>
    <td><p>Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_507">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05738317" target="_blank">NCT05738317</a></td><td><select class="form-select" id="select_form_15" name="NCT05738317"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Stage III NSCLC</td>
    <td>Guangdong Provincial People's Hospital</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_9">Study Arms</button></td>
    <td><p>Lorlatinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_508">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05740943" target="_blank">NCT05740943</a></td><td><select class="form-select" id="select_form_16" name="NCT05740943"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>ES-SCLC</td>
    <td>Xiaorong Dong</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_10">Study Arms</button></td>
    <td><p>Pembrolizumab Plinabulin plus Etoposide and Platinum</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_509">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05745350" target="_blank">NCT05745350</a></td><td><select class="form-select" id="select_form_17" name="NCT05745350"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Metastatic non-squamous NSCLC with asymptomatic untreated brain metastases</td>
    <td>Liza Villaruz MD</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_11">Study Arms</button></td>
    <td><p>Tiragolumab; Atezolizumab; Pemetrexed; Carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_510">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05746481" target="_blank">NCT05746481</a></td><td><select class="form-select" id="select_form_18" name="NCT05746481"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo2" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="6"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo2"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Non-small Cell Lung Cancer (NSCLC)</td>
    <td>Takeda</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_12">Study Arms</button></td>
    <td>No intervention</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05735327" target="_blank">NCT05735327</a></td><td><select class="form-select" id="select_form_19" name="NCT05735327"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Small Cell Lung Cancer (SCLC)</td>
    <td>Amgen</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_13">Study Arms</button></td>
    <td><p>Tarlatamab; Lurbinectedin; Topotecan; Amrubicin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_512">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05740566" target="_blank">NCT05740566</a></td><td><select class="form-select" id="select_form_20" name="NCT05740566"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_1" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive Preconditioning Lymphodepletion (PCLD) Regimen followed by a single dose of A2B530 intravenously on day 0</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Diagnostic Test: xT-Onco with HLA-LOH Assay; Biological: A2B530</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose level|Phase 1: Recommended Phase 2 Dose (RP2D)|Phase 2: The Overall Response Rate (ORR) for patients</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The RP2D will be identified utilizing a BOIN study design in addition to considering safety and biomarker analysis.; Adverse Events and toxicity will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5.0 (or current version). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) events will be graded according to the criteria described in the current protocol.; The ORR will be evaluated per RECIST v1.1 and assessed by independent central review.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>24 months post A2B530 infusion; 21 days post A2B530 infusion; From the time of Informed consent until 24 months (2 years) post A2B530 infusion.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_2" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose Escalation/Evaluation|MRTX1133 recommended Phase 2 dose administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12D mutation to include the following: NSCLC PDAC CRC Other Solid Tumors</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: MRTX1133</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1: Number of Patients who Experience Dose-Limiting Toxicity|Phase 1/1b: Number of patients who experience a treatment-related adverse event|Phase 2: Objective response rate (ORR)|Phase 2: Duration of response (DOR)|Phase 2: Progression free survival (PFS)|Phase 2: Overall survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years; 2 years; 21 Days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_3" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>BCD-201 200 mg by intravenous infusions once every 3 weeks|Keytruda 200 mg by intravenous infusions once every 3 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BCD-201; Drug: Keytruda</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>AUC(0-504) of pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>area under the drug concentration-time curve in the time interval from 0 to 504 hours</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>pre-dose to week 25 77 timepoints</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_4" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cohort 1:||Treatment period (3 weeks/cycle): On the first day of each cycle F520 (200 mg) pemetrexed and carboplatin were administered sequentially by intravenous infusion (at least 30 min between doses).||Maintenance period (3 weeks/cycle): On the first day of each cycle F520 (200 mg) and pemetrexed were administered sequentially by intravenous infusion (at least 30 min between doses).||Cohort 2:||Treatment period (3 weeks/cycle): On the first day of each cycle F520 (200 mg) paclitaxel and carboplatin were administered sequentially by intravenous infusion (at least 30 min between doses).||Maintenance period (3 weeks/cycle): On the first day of each cycle F520 (200 mg) was administered sequentially by intravenous infusion (at least 30 min between doses).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Paclitaxel; Drug: Pemetrexed; Drug: F520; Drug: Carboplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR (CR+PR) as assessed by the investigator per RECIST v1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_5" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.||Following surgery patients will receive adjuvant treatment with IPH5201 and durvalumab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: IPH5201 + durvalumab + standard chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pathological Complete Response (pCR)|Adverse events (AEs) and serious adverse events (SAEs)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of patients with pathological Complete Response (pCR); Number of patients with adverse events (AEs) and serious adverse events (SAEs).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>16 weeks after the first dose of study intervention.; Until Day 90 after the last dose of study interventions.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_6" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: RC48-ADC; Drug: Pyrotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>maximal tolerance dose (MTD) of RC48-ADC combined with Pyrotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Maximum-tolerated dose (MTD) was defined as the highest dose level at which no more than one of six patients experienced DLT during the DLT assessment window.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>DLT will be evaluated on 28 days of observation period</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_7" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receiving Brigatinib as part of their first-line treatment in scope of their routine clinical practice within the frames of National Drug Program (NDP) will be observed at baseline and every 3 months ( 1 month) at routine follow-up for up to 33 months.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: No intervention</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Real-World Progression Free Survival (rwPFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>rwPFS is defined as the time from starting treatment to the time of radiographic progression according to Response evaluation criteria in solid tumors (RECIST) v1.1 criteria.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 33 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_8" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive tarlatamab as an intravenous (IV) infusion.|Participants will receive treatment per local standard of care (SOC).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lurbinectedin; Drug: Topotecan; Drug: Tarlatamab; Drug: Amrubicin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_9" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>CM+PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: PD-1/PD-L1 inhibitor; Drug: Centipeda minima+PD-1/PD-L1 inhibitor</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS)|the temperature|blood pressure|complete blood count|adverse event and severe adverse event</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>adverse event and severe adverse event according to NCI-CTC V5.0; Progression-free survival; Vital signs; laboratory index</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>through study completion an average of 2 year.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_10" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Adebrelimab: 20 mg/kg Adebrelimab is given on day 1 of each cycle with 1 dosing cycle every 3 weeks. The dosing time window may be 5 days but within 72 hours before each dose subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.||Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle with 1 dosing cycle every 3 weeks.||Albumin Paclitaxel: 100 mg/m2 Albumin Paclitaxel is given on days 1 8 and 15 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>6-month PFS rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>6-Month PFS Rates for Adebrelimab Combined with Bevacizumab and Albumin Paclitaxel in Patients with Advanced NSCLC Progressed by First-Line Immunotherapy Evaluated by Investigators</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_11" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will receive 12-week induction Lorlatinib followed by radical surgery or local radiotherapy or continue Lorlatinib through MDT and consolidation lorlatinib for up to 2 years.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lorlatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pathological Complete Response (pCR)|Progression-free Survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The pathological complete response is defined as the absence of residual tumor in both lung and regional lymph nodes after induction treatment and radical surgery.; The period after initiation of induction treatment till the time of disease progression (defined by response evaluation criteria in solid tumor criteria) or death.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>After surgery (approximately 2 weeks); From date of induction treatment till the date of first documented disease progression or death whichever came first assessed up to 48 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_12" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab Plinabulin plus Etoposide and Platinum</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>12-m PFS rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival is defined as the time from the first treatment to the first documented disease progression per RECIST 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From date of the first treatment to the first documented disease progression assessed up to 24 months.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_13" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Tiragolumab in combination with atezolizumab pemetrexed and carboplatin.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Tiragolumab; Drug: Atezolizumab; Drug: Pemetrexed; Drug: Carboplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Rate of Initiation of Salvage Radiation Therapy to Central Nervous System (CNS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The proportion of patients that require salvage radiation therapy to the CNS (within 18 weeks from study initiation). Salvage radiation therapy is radiation treatment given for suspected recurrent malignant disease.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 18 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## EXISTING LC ########## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_lc">Existing Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 445 days; Trial terminated; Primary Completion Date moved earlier by 830 days</strong></td>
    <td>Select advanced or metastatic solid tumors</td>
    <td>Advaxis Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_14">Study Arms</button></td>
    <td><p>ADXS-NEO; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_513">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03265080" target="_blank">NCT03265080</a></td><td><select class="form-select" id="select_form_21" name="NCT03265080"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date moved earlier by 699 days</strong></td>
    <td>Non-small-cell lung carcinoma urothelial carcinoma renal cell carcinoma melanoma or head-and-neck carcinoma</td>
    <td>University Hospital Ghent</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_15">Study Arms</button></td>
    <td><p>Nivolumab or Pembrolizumab or Atezolizumab; SBRT</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_513">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03511391" target="_blank">NCT03511391</a></td><td><select class="form-select" id="select_form_22" name="NCT03511391"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment increased by: 24; Trial completed; Primary Completion Date moved earlier by 637 days</strong></td>
    <td>Advanced or Metastatic NSCLC</td>
    <td>Innovent Biologics (Suzhou) Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_16">Study Arms</button></td>
    <td>Sintilimab (M1b); Sintilimab (approved)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04177290" target="_blank">NCT04177290</a></td><td><select class="form-select" id="select_form_23" name="NCT04177290"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active; Primary Completion Date moved earlier by 532 days</strong></td>
    <td>Advanced Solid Malignancies</td>
    <td>AO GENERIUM</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_17">Study Arms</button></td>
    <td>GNR-051</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04544748" target="_blank">NCT04544748</a></td><td><select class="form-select" id="select_form_24" name="NCT04544748"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 313 days; Enrollment decreased by: 50; Trial completed; Primary Completion Date moved earlier by 331 days</strong></td>
    <td>Advanced recurrent or metastatic non-small-cell lung cancer</td>
    <td>Innovent Biologics (Suzhou) Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_18">Study Arms</button></td>
    <td>Sintilimab; IBI310</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05118334" target="_blank">NCT05118334</a></td><td><select class="form-select" id="select_form_25" name="NCT05118334"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date moved earlier by 326 days</strong></td>
    <td>Advanced solid tumors melanoma non-small cell lung cancer (NSCLC) and renal cell carcinoma</td>
    <td>Yale University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_19">Study Arms</button></td>
    <td><p>APX005M; Cabiralizumab; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_516">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03502330" target="_blank">NCT03502330</a></td><td><select class="form-select" id="select_form_26" name="NCT03502330"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 184 days; Primary Completion Date moved earlier by 278 days</strong></td>
    <td>Non-Small Cell Lung Cancer</td>
    <td>Case Comprehensive Cancer Center</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_20">Study Arms</button></td>
    <td><p>Durvalumab; Proton beam therapy RT</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_516">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03818776" target="_blank">NCT03818776</a></td><td><select class="form-select" id="select_form_27" name="NCT03818776"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 392 days; Enrollment decreased by: 28; Trial completed; Primary Completion Date moved earlier by 117 days</strong></td>
    <td>Non-small Cell Lung Cancer</td>
    <td>Oxford University Hospitals NHS Trust</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_21">Study Arms</button></td>
    <td>Inhalation of hyperpolarized xenon gas</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02151604" target="_blank">NCT02151604</a></td><td><select class="form-select" id="select_form_28" name="NCT02151604"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 276 days; Trial completed; Primary Completion Date moved earlier by 114 days</strong></td>
    <td>Small Cell Lung Cancer</td>
    <td>Innovent Biologics (Suzhou) Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_22">Study Arms</button></td>
    <td><p>paclitaxel; IBI318</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04672928" target="_blank">NCT04672928</a></td><td><select class="form-select" id="select_form_29" name="NCT04672928"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 558 days</strong></td>
    <td>Locally advanced non-small cell lung cancer</td>
    <td>Washington University School of Medicine</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_23">Study Arms</button></td>
    <td><p>ViewRay MR-Linear Accelerator; Radiation therapy; Paclitaxel; Carboplatin AUC; Durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03916419" target="_blank">NCT03916419</a></td><td><select class="form-select" id="select_form_30" name="NCT03916419"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from suspended to active</strong></td>
    <td>Relapsed or extrapulmonary small cell lung cancer</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_24">Study Arms</button></td>
    <td><p>Berzosertib; Biopsy; Biospecimen Collection; Computed Tomography; Topotecan Hydrochloride</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03896503" target="_blank">NCT03896503</a></td><td><select class="form-select" id="select_form_31" name="NCT03896503"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>EGFR mutated advanced non-small cell lung cancer</td>
    <td>National Taiwan University Hospital</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_25">Study Arms</button></td>
    <td><p>Atezolizumab Injection; bevacizumab Injection</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04147351" target="_blank">NCT04147351</a></td><td><select class="form-select" id="select_form_32" name="NCT04147351"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Trial completed</strong></td>
    <td>Advanced or metastatic Non-squamous NSCLC</td>
    <td>Innovent Biologics (Suzhou) Co. Ltd.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_26">Study Arms</button></td>
    <td><p>Sintilimab; Pemetrexed; Platinum; Placebos</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03607539" target="_blank">NCT03607539</a></td><td><select class="form-select" id="select_form_33" name="NCT03607539"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>Dracen Pharmaceuticals Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_27">Study Arms</button></td>
    <td><p>DRP-104; atezolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04471415" target="_blank">NCT04471415</a></td><td><select class="form-select" id="select_form_34" name="NCT04471415"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 27; Trial terminated; Start Date pushed later by 168 days</strong></td>
    <td>EGFR T790M mutated NSCLC</td>
    <td>First Affiliated Hospital of Zhejiang University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_28">Study Arms</button></td>
    <td><p>osimertinib mesylate tablets and anlotinib hydrochloride capsules</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04438902" target="_blank">NCT04438902</a></td><td><select class="form-select" id="select_form_35" name="NCT04438902"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Low to intermediate grade (Grade 1 or Grade 2) well-differentiated neuroendocrine tumours</td>
    <td>Hutchmed</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_29">Study Arms</button></td>
    <td>Surufatinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04579679" target="_blank">NCT04579679</a></td><td><select class="form-select" id="select_form_36" name="NCT04579679"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from not yet recruiting to suspended; Start Date pushed later by 365 days</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>I-Mab Biopharma Co. Ltd.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_30">Study Arms</button></td>
    <td><p>TJ271 Injection in Combination with Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_518">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05338580" target="_blank">NCT05338580</a></td><td><select class="form-select" id="select_form_37" name="NCT05338580"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>First Affiliated Hospital of Zhejiang University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_31">Study Arms</button></td>
    <td><p>Paclitaxel Micelles for Injection; Paclitaxel injection</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_518">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04778839" target="_blank">NCT04778839</a></td><td><select class="form-select" id="select_form_38" name="NCT04778839"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Advanced solid tumors</td>
    <td>Instil Bio</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_32">Study Arms</button></td>
    <td>ITIL-306</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05397093" target="_blank">NCT05397093</a></td><td><select class="form-select" id="select_form_39" name="NCT05397093"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting; Start Date pushed later by 92 days</strong></td>
    <td>Resectable stage IIB to IIIA non-small cell lung cancer</td>
    <td>Galvanize Therapeutics Inc.</td>
<td><p>Phase 4</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_33">Study Arms</button></td>
    <td><p>Aliya Pulsed Electric Fields (PEF) ablation; Nivolumab plus Platinum Doublet Chemotherapy; Standard of care neoadjuvant therapy; Surgical Resection</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_519">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05583188" target="_blank">NCT05583188</a></td><td><select class="form-select" id="select_form_40" name="NCT05583188"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting; Start Date moved earlier by 130 days</strong></td>
    <td>Relapsed or refractory metastatic NSCLC</td>
    <td>Jeffrey Clarke</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_34">Study Arms</button></td>
    <td><p>Pembrolizumab; GT103</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_519">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05617313" target="_blank">NCT05617313</a></td><td><select class="form-select" id="select_form_41" name="NCT05617313"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Advanced Lung Cancer</td>
    <td>Shanghai Junshi Bioscience Co. Ltd.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_35">Study Arms</button></td>
    <td><p>Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection; Toripalimab; Docetaxel; Pemetrexed; Cisplatin; Carboplatin; Paclitaxel; Etoposide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_519">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05664971" target="_blank">NCT05664971</a></td><td><select class="form-select" id="select_form_42" name="NCT05664971"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Solid Tumors</td>
    <td>DEKA Biosciences</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_36">Study Arms</button></td>
    <td>DK210 (EGFR); Radiation therapy; Immune checkpoint blockers; Chemotherapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05704985" target="_blank">NCT05704985</a></td><td><select class="form-select" id="select_form_43" name="NCT05704985"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 94 days</strong></td>
    <td>Advanced or metastatic solid tumors</td>
    <td>NextCure Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_37">Study Arms</button></td>
    <td>NC318</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03665285" target="_blank">NCT03665285</a></td><td><select class="form-select" id="select_form_44" name="NCT03665285"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 124 days</strong></td>
    <td>Metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL)</td>
    <td>CytomX Therapeutics</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_38">Study Arms</button></td>
    <td>CX-2029</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03543813" target="_blank">NCT03543813</a></td><td><select class="form-select" id="select_form_45" name="NCT03543813"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Locally advanced or metastatic non-small cell lung cancer</td>
    <td>Incyte Corporation</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_39">Study Arms</button></td>
    <td>Itacitinib; Osimertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02917993" target="_blank">NCT02917993</a></td><td><select class="form-select" id="select_form_46" name="NCT02917993"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Stage III non-small cell lung cancer that cannot be removed by surgery</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_40">Study Arms</button></td>
    <td><p>3-Dimensional Conformal Radiation Therapy; Carboplatin; Laboratory Biomarker Analysis; Paclitaxel; Placebo Administration; Veliparib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_523">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01386385" target="_blank">NCT01386385</a></td><td><select class="form-select" id="select_form_47" name="NCT01386385"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Non-small cell lung cancer</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_41">Study Arms</button></td>
    <td><p>3-Dimensional Conformal Radiation Therapy; Intensity-Modulated Radiation Therapy; Laboratory Biomarker Analysis; Pembrolizumab; Proton Beam Radiation Therapy; Radiation Therapy; Stereotactic Body Radiation Therapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_523">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02444741" target="_blank">NCT02444741</a></td><td><select class="form-select" id="select_form_48" name="NCT02444741"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>Celon Pharma SA</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_42">Study Arms</button></td>
    <td>CPL304110</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04149691" target="_blank">NCT04149691</a></td><td><select class="form-select" id="select_form_49" name="NCT04149691"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 396 days</strong></td>
    <td>Locally-advanced NSCLC (stage II/III)</td>
    <td>Wake Forest University Health Sciences</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_43">Study Arms</button></td>
    <td><p>SBRT; Carboplatin; Paclitaxel; cis Platinum; Etoposide; IMRT; Durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_524">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03141359" target="_blank">NCT03141359</a></td><td><select class="form-select" id="select_form_50" name="NCT03141359"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 620 days; Enrollment increased by: 120</strong></td>
    <td>Advanced solid tumors including RET Fusion-Positive NSCLC or RET-mutated MTC or other RET-altered advanced solid tumor</td>
    <td>Shouyao Holdings (Beijing) Co. LTD</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_44">Study Arms</button></td>
    <td>SY-5007</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05278364" target="_blank">NCT05278364</a></td><td><select class="form-select" id="select_form_51" name="NCT05278364"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 731 days</strong></td>
    <td>Non-Small-Cell Lung Cancer</td>
    <td>BioAtla Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_45">Study Arms</button></td>
    <td>CAB-AXL-ADC; PD-1 inhibitor</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04681131" target="_blank">NCT04681131</a></td><td><select class="form-select" id="select_form_52" name="NCT04681131"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 487 days; Primary Completion Date pushed later by 90 days</strong></td>
    <td>Unresectable stage III NSCLC and ALK-rearrangement</td>
    <td>ETOP IBCSG Partners Foundation</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_46">Study Arms</button></td>
    <td><p>Brigatinib; Durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_526">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05718297" target="_blank">NCT05718297</a></td><td><select class="form-select" id="select_form_53" name="NCT05718297"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Trial completed; Primary Completion Date pushed later by 121 days</strong></td>
    <td>Small Cell Lung Cancer Recurrent</td>
    <td>Taizhou Hospital</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_47">Study Arms</button></td>
    <td>S1/Anlotinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03823118" target="_blank">NCT03823118</a></td><td><select class="form-select" id="select_form_54" name="NCT03823118"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 305 days; Primary Completion Date pushed later by 275 days</strong></td>
    <td>Breast Cancer; Non-small Cell Lung Carcinoma</td>
    <td>Daiichi Sankyo Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_48">Study Arms</button></td>
    <td><p>Trastuzumab deruxtecan (DS-8201a); Trastuzumab deruxtecan (DS-8201a); Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_527">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04042701" target="_blank">NCT04042701</a></td><td><select class="form-select" id="select_form_55" name="NCT04042701"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 336 days</strong></td>
    <td>Locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation</td>
    <td>Tempus Labs</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_49">Study Arms</button></td>
    <td>Niraparib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05169437" target="_blank">NCT05169437</a></td><td><select class="form-select" id="select_form_56" name="NCT05169437"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 731 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Non-small Cell Lung Cancer</td>
    <td>University Hospital Ghent</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_50">Study Arms</button></td>
    <td>Dendritic cell immunotherapy; Antigen-specific DTH; Control DTH</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04078269" target="_blank">NCT04078269</a></td><td><select class="form-select" id="select_form_57" name="NCT04078269"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days; Primary Completion Date pushed later by 731 days</strong></td>
    <td>Non-Small Cell Lung Cancer</td>
    <td>Affiliated Cancer Hospital & Institute of Guangzhou Medical University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_51">Study Arms</button></td>
    <td>Surufatinib; Surufatinib Plus Vinorelbine</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04922658" target="_blank">NCT04922658</a></td><td><select class="form-select" id="select_form_58" name="NCT04922658"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 1188 days; Primary Completion Date pushed later by 731 days</strong></td>
    <td>HER2 Positive Solid Tumors</td>
    <td>Bolt Biotherapeutics Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_52">Study Arms</button></td>
    <td><p>BDC-1001; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_530">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04278144" target="_blank">NCT04278144</a></td><td><select class="form-select" id="select_form_59" name="NCT04278144"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 1461 days; Changed status from unknown status to suspended; Primary Completion Date pushed later by 1095 days</strong></td>
    <td>Interstitial Lung Disease</td>
    <td>National Institute for Tuberculosis and Lung Diseases Poland</td>
<td><p>Phase 4</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_53">Study Arms</button></td>
    <td><p>Prolonged glucocorticosteroid (prednisone) regimen; Short glucocorticosteroid (prednisone) regimen</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_530">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04036721" target="_blank">NCT04036721</a></td><td><select class="form-select" id="select_form_60" name="NCT04036721"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 1096 days; Primary Completion Date pushed later by 1461 days</strong></td>
    <td>Advanced or metastatic solid tumors</td>
    <td>Institut Bergoni</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_54">Study Arms</button></td>
    <td><p>Phase 1 : Regorafenib; Phase 1 : Avelumab; Phase 2 : Regorafenib; Phase 2 : Avelumab; Phase 2: low-dose Regorafenib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_530">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03475953" target="_blank">NCT03475953</a></td><td><select class="form-select" id="select_form_61" name="NCT03475953"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 121 days</strong></td>
    <td>Lung Cancer</td>
    <td>Stanford University</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_55">Study Arms</button></td>
    <td>18F-C-SNAT4; Positron emission tomography (PET)/Computed tomography (CT) Scan</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04017819" target="_blank">NCT04017819</a></td><td><select class="form-select" id="select_form_62" name="NCT04017819"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 243 days</strong></td>
    <td>EGFR-mutant non-small cell lung cancer that has spread to other places in the body (advanced or metastatic)</td>
    <td>Shanghai EpimAb Biotherapeutics Co. Ltd.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_56">Study Arms</button></td>
    <td>EMB-01; Osimertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05498389" target="_blank">NCT05498389</a></td><td><select class="form-select" id="select_form_63" name="NCT05498389"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo3" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo3"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 169 days; Primary Completion Date moved earlier by 229 days</strong></td>
    <td>Solid tumors</td>
    <td>Pfizer</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_57">Study Arms</button></td>
    <td><p>PF-07799544; PF-07284890; PF-07799933; encorafenib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_532">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05538130" target="_blank">NCT05538130</a></td><td><select class="form-select" id="select_form_64" name="NCT05538130"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 341 days; Enrollment decreased by: 82; Changed status from recruiting to active</strong></td>
    <td>BRAF V600-mutated advanced solid tumor malignancies</td>
    <td>Pfizer</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_58">Study Arms</button></td>
    <td><p>PF-07284890; Binimetinib; Midazolam</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_532">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04543188" target="_blank">NCT04543188</a></td><td><select class="form-select" id="select_form_65" name="NCT04543188"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 102 days; Expanded Access Status For N C T Id now No longer available; Trial terminated</strong></td>
    <td>Tumor</td>
    <td>Bristol-Myers Squibb</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_59">Study Arms</button></td>
    <td><p>ipilimumab; nivolumab; ENHANZE (rHuPH20); nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_532">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04311710" target="_blank">NCT04311710</a></td><td><select class="form-select" id="select_form_66" name="NCT04311710"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 28</strong></td>
    <td>Relapsed/Refractory Small Cell Lung Cancer</td>
    <td>Amgen</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_60">Study Arms</button></td>
    <td>Tarlatamab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05060016" target="_blank">NCT05060016</a></td><td><select class="form-select" id="select_form_67" name="NCT05060016"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment increased by: 82</strong></td>
    <td>Castration Resistant Prostate Cancer (CRPC); Small Cell Lung Cancer (SCLC); Follicular Lymphoma (FL)</td>
    <td>Pfizer</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_61">Study Arms</button></td>
    <td>PF-06821497</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03460977" target="_blank">NCT03460977</a></td><td><select class="form-select" id="select_form_68" name="NCT03460977"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 92</strong></td>
    <td>Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer</td>
    <td>Pfizer</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_62">Study Arms</button></td>
    <td><p>PF-07248144; Fulvestrant; Letrozole; Palbociclib; PF-07220060</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_534">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04606446" target="_blank">NCT04606446</a></td><td><select class="form-select" id="select_form_69" name="NCT04606446"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 364 days</strong></td>
    <td>Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive</td>
    <td>AstraZeneca</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_63">Study Arms</button></td>
    <td>AZD9291</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02094261" target="_blank">NCT02094261</a></td><td><select class="form-select" id="select_form_70" name="NCT02094261"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 670 days; Enrollment increased by: 40</strong></td>
    <td>KRAS G12C mutated cancer</td>
    <td>Eli Lilly and Company</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_64">Study Arms</button></td>
    <td><p>LY3537982; Abemaciclib; Pembrolizumab; LY3295668; Cetuximab; Pemetrexed; Cisplatin; Carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_535">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04956640" target="_blank">NCT04956640</a></td><td><select class="form-select" id="select_form_71" name="NCT04956640"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Primary Completion Date pushed later by 705 days</strong></td>
    <td>Solid Tumors Harboring NTRK Fusion</td>
    <td>Bayer</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_65">Study Arms</button></td>
    <td>BAY2757556 (Larotrectinib Vitrakvi)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02576431" target="_blank">NCT02576431</a></td><td><select class="form-select" id="select_form_72" name="NCT02576431"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_14" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort also known as intra-cohort staggering.||Two dose levels of ADXS-NEO will be explored: 1 x 10^9 and 1 x 10^8 colony forming unit (CFU).|Two dose levels of ADXS-NEO will be explored (i.e. 1 x 10^8 and 5 x 10^8 CFU) in combination with 200 mg of pembrolizumab.|ADXS-NEO will be explored at 1 x 10^8 CFU in combination with 200 mg of pembrolizumab in an expansion cohort.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: ADXS-NEO; Biological: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of Treatment-Emergent Adverse Events|Maximum tolerated dose</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>4 weeks; From the first dose up to 20 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_15" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:||Nivolumab or Pembrolizumab or Atezolizumab + SBRT|Checkpoint inhibitor treatment only:||Nivolumab or Pembrolizumab or Atezolizumab monotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: SBRT; Drug: Nivolumab or Pembrolizumab or Atezolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival will be defined as the time from randomization to disease progression (as per iRECIST) or death from any cause.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>15 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_16" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Sintilimab (M1b); Drug: Sintilimab (approved)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>PK is defined as AUC0-.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_17" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>GNR-051 (0.1 mg/kg)|GNR-051 (0.3 mg/kg)|GNR-051 (1 mg/kg)|GNR-051 (3 mg/kg)|GNR-051 (10 mg/kg)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: GNR-051</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum Tolerated Dose (MTD)|Number of participants with dose-limiting toxicity (DLT)|Laboratory tests|Vital signs|Physical examination|12-lead electrocardiogram|ECOG assessment|Antidrug antibody</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Tolerability of GNR-051; Safety profile of GNR-051; All adverse events (CTCAE 5.0)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>36 Months; 28 Days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_18" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The test group will be treated with IBI310 1mg/kg IV Q3W+ Sintilimab 200 mg IV Q3W until progressive diseaseintolerable toxicity start of a new antitumor treatment withdrawal of informed consent loss to follow-up death or other situations requiring termination of treatment specified in the protocol whichever occurs first.|The test group will be treated with IBI310 1mg/kg IV Q3W+ Sintilimab 200 mg IV Q3W*4cyclesand then Sintilimab 200 mg IV Q3W single until progressive diseaseintolerable toxicity start of a new antitumor treatment withdrawal of informed consent loss to follow-up death or other situations requiring termination of treatment specified in the protocol whichever occurs first.|The test group will be treated with IBI310 1mg/kg IV Q6W+ Sintilimab 200 mg IV Q3Wuntil progressive diseaseintolerable toxicity start of a new antitumor treatment withdrawal of informed consent loss to follow-up death or other situations requiring termination of treatment specified in the protocol whichever occurs first.|The test group will be treated with IBI310 0.5mg/kg IV Q3W+ Sintilimab 200 mg IV Q3W until progressive diseaseintolerable toxicity start of a new antitumor treatment withdrawal of informed consent loss to follow-up death or other situations requiring termination of treatment specified in the protocol whichever occurs first.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Sintilimab; Drug: IBI310</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate(ORR)|Treatment Emergent Adverse Event (TEAE)|Severe Adverse Event (SAE)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Incidence and severity of treatment-emergent: which is evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0) grade;; Investigator evaluated ORR per RECIST V1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_19" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.|Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.|Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: APX005M; Drug: Cabiralizumab; Drug: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety and Tolerability measured by assessing serious adverse events (SAEs)and adverse events (AEs)|Safety and Tolerability measured by Eastern Cooperative Oncology Group(ECOG) performance status</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>This 5-point scale ranges from full functioning (1) to dead (5); AEs and SAEs will be examined with (National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From study enrollment up to 12 months.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_20" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.||Radiation will follow dose escalation scheme:||60 CGyE in 20 fractions (3+3 participants 3-6 total)|Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.||Radiation will follow dose escalation scheme:||69 CGyE in 23 fractions (3+3 participants 3-6 total) Followed by expansion cohort at identified RP2 dose (12 participants)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: Proton beam therapy RT; Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety of intervention as defined by number of participants with Dose Limiting Toxicities (DLT) between first dose of Durvalumab and 30 days following completion of radiotherapy.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Grade 3 or higher cardiac adverse events (e.g. severely symptomatic congestive heart failure (CHF) myocarditis pericardial effusion myocardial infarction symptomatic arrhythmia) considered by the Investigators to be probably or definitely related to protocol treatment.; Failure to receive at least 54; Safety of intervention as defined by number of participants with DLT's between first dose of Durvalumab and 30 days following completion of radiotherapy. This is defined as 0 of 3 or 1 of 6 participants having no DLT of either Durvalumab or RT.; DLT for RT defined as:; Grade 4-5 non-hematologic serious adverse events (SAEs) considered by the Investigators to be probably or definitely related to protocol treatment.; Grade 3 or higher pulmonary adverse events (e.g. dyspnea/pneumonitis) considered by the Investigators to be probably or definitely related to protocol treatment and not responsive to steroids.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 days following end of treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_21" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Inhalation of hyperpolarized xenon gas</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of participants with a change from baseline in ventilation map using hyperpolarized Xe-129</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Mid-point of radiotherapy - varies depending on the duration of treatment prescribed between 1 week to 2 months from the baseline scan (range: 7 days to 60 days). For example for 2 weeks of radiotherapy this would be at 1 week post-baseline.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_22" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: paclitaxel; Drug: IBI318</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Adverse events|Objective remission rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The incidence rate of all treatment-emergent adverse events (TEAEs) immune-related adverse events (irAEs) and serious adverse events (SAEs) treatment-related adverse events (TRAEs) and the severity.; Proportion of subjects with complete response (CR) or partial response (PR).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 months; 3 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_23" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events.|Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6 9 and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of treating physician) for up to 12 months.|-Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6 9 and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of the treating physician) for up to 12 months.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Paclitaxel; Drug: Carboplatin AUC; Radiation: Radiation therapy; Device: ViewRay MR-Linear Accelerator; Biological: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety lead-in only: Number of participants with dose limiting toxicities (DLTs)|Local control rate (Phase II only)|Regional control rate (Phase II only)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>-Clinical and/or radiographic evidence of progression of disease at the primary (local) site; The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.; DLT is defined as any possibly probably or definitely related to concurrent chemoradiation grade 3 toxicity that cannot be managed with maximal supportive care within 2 weeks or any grade  4 toxicity that occurs during treatment; Safety of hypofractionated MRI-guided adaptive radiotherapy (60Gy/15 fractions) with concurrent chemotherapy (carboplatin and paclitaxel) and consolidation durvalumab is defined as 2/6 participants experiencing dose limiting toxicities; -Clinical and/or radiographic evidence of progression of disease at the previously involved or uninvolved hilar and/or mediastinal nodal (regional) sites</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through 6 months after completion of concurrent chemoradiation (estimated to be 6 months and 3 weeks); Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_24" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II at disease progression. Patients undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Patients may also undergo blood sample collection during screening and on study.|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 and M6620 IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Patients may also undergo blood sample collection during screening and on study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Topotecan Hydrochloride; Drug: Berzosertib; Procedure: Computed Tomography</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The combination of M6620 with topotecan will be compared to topotecan alone in patients with relapsed small cell lung cancer (SCLC). Kaplan-Meier curves and a one-tailed log-rank test will be the primary analysis methods.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From start of treatment to time of progression or death whichever occurs first assessed at 6 months after last patient has enrolled</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_25" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Atezolizumab Injection; bevacizumab Injection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The percentage of patients with radiologically complete or partial response as determined by the investigator according to RECIST version 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>9 MONTHS</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_26" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W (qualer 3 weeks); duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains|placebo 2 vials + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Sintilimab; Drug: Pemetrexed; Drug: Platinum; Drug: Placebos</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS was defined as the time from randomization to the first documented PD or death due to any cause whichever occurred first. Per RECIST 1.1 PD was defined as 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20% the sum must also have demonstrated an absolute increase of 5 mm. The appearance of one or more new lesions was also considered PD</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_27" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 of 3.3 mg/m2 via intravenous injection||Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 at 10 mg via subcutaneous injection|Cohort 1: Phase 1 single-agent safety expansion of DRP-104 administered subQ (the RP2R) in patients with advanced solid tumors (excluding primary CNS tumors and HCC). DRP-104 will be administered twice weekly subQ in this safety expansion at the twice weekly subQ MTD/MAD/RP2D of DRP-104 determined in Part 1-Cohort 1b. A minimum of 14 and up to 20 patients will be enrolled.||Cohort 2: Phase 2a expansion at the MTD/MAD/RP2D/RP2R and schedule of administration (subQ twice or thrice weekly) of DRP-104 in patients with locally advanced or metastatic NSCLC whose tumors contain a known mutation in kelchlike ECH-associated protein 1 (KEAP1) nuclear factor erythroid 2-related factor 2 (NFE2L2) and/or serine/threonine kinase 11 (STK11) (N=55). If the thrice weekly schedule is selected as the RP2S a safety review will be conducted after 8 patients have enrolled and are followed for at least one cycle of treatment before additional patients are enrolled into Part 2-Cohort 2.|Phase 1 combination dose escalation of DRP-104 and atezolizumab in patients with advanced solid tumors (excluding primary CNS tumors and HCC) previously treated with an agent targeting checkpoint pathway inhibition (such as anti-PD-1 anti-PD-L1 and/or anti-CTLA-4 antibody) starting one dose level below the MTD/MAD/RP2D (MTD-1) of the recommended phase 2 route and schedule of administration of singleagent DRP-104 and in combination with 1200 mg atezolizumab administered via intravenous infusion on day 1 and repeated every 3 weeks (up to approximately 12 patients);|Phase 1 combination safety expansion at the MTD/MAD/RP2D route and schedule of administration of DRP-104 with atezolizumab in a similar patient population as the dose-escalation (N=14 patients).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: DRP-104; Biological: atezolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum Tolerated Dose (MTD)|Pharmacokinetics (PK) of DRP-104|Cmax of DRP-104|Overall Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess and compare the concentration and partitioning of DRP-104 and the metabolites M1 and DON; Area under the plasma concentration versus time curve (AUC); Using RECIST criteria determine the Overall Response Rate for DRP-104 subQ in NSCLC cohort 2 (months); Safety</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>anticipated 1 year; anticipated 2 year; anticipated 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_28" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: osimertinib mesylate tablets and anlotinib hydrochloride capsules</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>progression-free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is defined as the time from beginning of osimertinib to disease progression on combination treatment of osimertinib and anlotinib.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>from the date of first dose of osimertinib until the date of disease progressionassessed up to 12 months.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_29" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cohorts A B and C: oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1||Cohort D:||Surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day and single doses of drug cocktail on Day-2 and Day 15 Cycle 1</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Surufatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Disease Control Rate (DCR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Disease control rate the incidence of complete response partial response and stable disease.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_30" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TJ271 Injection in Combination with Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To evaluate the anti-tumor efficacy of TJ271 in combination with pembrolizumab in patients with advanced solid tumors i.e. to evaluate the Objective Response Rate (ORR) as per RECIST 1.1 criteria</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>approximately 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_31" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>In the First Period Only three Participants in the first dose group were randomly assigned to 175 mg/m2 paclitaxel micelle for injection at a 1:1 rate.175 mg/m2 260 mg/m2 320 mg/m2 and 390 mg/m2 of paclitaxel micelle for Injection was intravenously administrated for three hoursthree weeks constituted one course of treatment.|three Participants were randomly assigned to 175 mg/m2 paclitaxel Injection175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours three weeks constituted one course of treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Paclitaxel injection; Drug: Paclitaxel Micelles for Injection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety and tolerability of Paclitaxel Micelles for Injection in dose ascending and dose extension as measured by assessment of maximum tolerated dose (MTD) and dose limiting toxicity (DLT).|The recommended dose for the phase II study</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>MTD was determined as the dose where more than 2 out of 6 subjects experienced DLT; Determined as the recommended dose for a phase 2 study based on the adverse events and toxicities at each dose groups</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_32" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Various doses will be tested in participants with EOC NSCLC and RCC.|Cohort 1: Participants with epithelial ovarian cancer (EOC)||Cohort 2: Participants with non-small cell lung cancer (NSCLC)||Cohort 3: Participants with renal cell carcinoma (RCC)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: ITIL-306</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency and severity of ITIL-306 treatment-emergent adverse events (AEs) serious AEs and AEs of special interest (AESI)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_33" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pulsed electric field treatment using the Aliya System</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Device: Aliya Pulsed Electric Fields (PEF) ablation; Other: Surgical Resection; Drug: Standard of care neoadjuvant therapy; Drug: Nivolumab plus Platinum Doublet Chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pathologic response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Pathologic response (percentage of residual viable tumor cells) of the resected lesion ablated with PEF and in resected lymph nodes in patients who received standard of care neoadjuvant nivolumab plus chemotherapy prior to resection.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Surgical resection</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_34" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pembrolizumab will be given intravenously on Day 1 of the 21 day cycle (For all cycles).||GT103 dose will be determined by the safety lead in prior to the study. Dosing calculations should be based on actual body weight where applicable. It will be taken intravenously on Day 1 of the 21 day cycle (For all cycles).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: GT103; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)|Assess the Frequency and Severity of Adverse Events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR will be defined as the proportion of patients with radiographic complete or partial response rate per RECIST v1.1.; Safety and tolerability will be assessed by the proportion of patients with DLT observed during the first cycle of treatment. NCI CTCAE v5 will be used to grade adverse events.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 years; 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_35" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>NSCLC-squamous carcinoma third line;JS004 200mg + JS001 240mg Q3w maintained until disease progression|NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w maintained until disease progression|NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed maintained until disease progression|NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w for 4 cycles; JS004 200mg + JS001 240 mg maintained until disease progression|SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w for 4 cycles; JS004 200mg + JS001 240 mg maintained until disease progression</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Paclitaxel; Drug: Pemetrexed; Drug: Carboplatin; Biological: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection; Drug: Docetaxel; Biological: Toripalimab; Drug: Cisplatin; Drug: Etoposide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs)|Incidence of SAEs|Incidence of irAEs|ORR</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Incidence of immune-related adverse events (irAEs); Efficacy endpoint: objective response rate (ORR) based on RECIST v1.1 criteria; Incidence of adverse events (AEs); Incidence of serious adverse events (SAEs)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_36" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>DK210 (EGFR) will be administered as monotherapy three times per week via subcutaneous (SC) administration. Dose will be escalated from 0.025 mg/kg to 0.3 mg/kg or until unacceptable toxicity disease progression or withdrawal of consent. An expansion cohort at the optimal dose will be enrolled in parallel with the combination arms.|In patients with good tolerance of first line systemic therapy DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with second-line intravenous (IV) chemotherapy until unacceptable toxicity disease progression or withdrawal of consent|In patients with need of palliative radiation DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with short course radiation therapy (10 fractions or less) until unacceptable toxicity disease progression or withdrawal of consent|In patients with good tolerance of first line immunotherapy DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with intravenous (IV) immune checkpoint blockers until unacceptable toxicity disease progression or withdrawal of consent</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Immune checkpoint blockers; Radiation: Radiation therapy; Drug: Chemotherapy; Biological: DK210 (EGFR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of Adverse Events (AEs) with DK210 (EGFR)|Identify recommended dose of DK210 (EGFR)|Incidence of Adverse Events (AE) of DK210 (EGFR) in combination with radiation chemotherapy or checkpoint blockers in Parts B C D</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Based on toxicities observed</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Minimum of 90 days from initiation of experimental therapy; Initiation of therapy up to day 90</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_37" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>NC318 for IV infusion of various dose strengths administered in 14 day dosing cycles. Alternative dosing schedules may be explored once RP2D has been determined.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: NC318</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with treatment-emergent Adverse Events as assessed by CTCAE v5.0|Define a maximum tolerated dose (MTD) or pharmacologically active dose (PAD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A 3 + 3 design will be utilized to determine the MTD of NC318; Frequency duration and severity of treatment-emergent adverse events (AEs)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 14 months; 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_38" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose Escalation and Determination|Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types|Evaluate antitumor activity of CX-2029</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: CX-2029</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>21 days (dose-limiting toxicity period)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_39" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Osimertinib; Drug: Itacitinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1: Frequency severity and duration of adverse events (AEs)|Phase 1: Number of subjects with dose-limiting toxicities (DLTs)|Phase 2: Objective response rate (ORR) based on RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR defined as the percentage of subjects who have a confirmed best overall response of complete response (CR) or partial response (PR).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 1 through Day 28; Screening and 8-week intervals throughout the study approximately 2 years.; From screening through 30-35 days after end of treatment approximately 2 years.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_40" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients undergo 3D-CRT and receive veliparib carboplatin and paclitaxel as in Phase I induction and consolidation therapy.|Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Paclitaxel; Drug: Carboplatin; Drug: Veliparib; Other: Placebo Administration; Other: Laboratory Biomarker Analysis</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum Tolerated Dose of Veliparib When Given Concurrently With Standard Carboplatin/Paclitaxel and Radiotherapy Determined According to Incidence of Dose Limiting Toxicity (DLT) (Phase I)|Progression-free Survival of Patients Treated With Chemoradiotherapy Plus Veliparib (Phase II)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause. Participants last known to be alive are censored at date of last contact.; Delays in radiotherapy or chemotherapy or ABT-888 due to toxicity of  3 weeks; DLTs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. DLTs must be attributable (probably possibly definitely related) to the study regimen and only occur during RT or 2 weeks after completing RT.; Grade 4 neutropenia for  7 days or neutropenic fever ( ANC 500 and temperature = 38.5 oC); anorexia; infection without neutropenia; fatigue; Grade 4 nausea/vomiting despite appropriate antiemetic therapy; Grade 3 or 4 lymphopenia; Assessed by Response Evaluation Criteria in Solid Tumors RECIST 1.1; Grade 3 or 4 electrolyte abnormalities that are corrected to =Grade 2 in  48 hours; DLTs are defined as:; Grade 3 AST/ALT elevations = 7 days infusion reactions; Grade 3 dehydration lasting  7 days; All other non-hematologic toxicities = Grade 3 except; Radiation esophagitis or dermatitis radiation Grade 3 that lasts  7 consecutive days or Grade 4; Grade 4 thrombocytopenia</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>The time from randomization to progression or death due to any cause assessed up to 5 years; 9 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_41" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients who exhibit a lung lesion of size and location amenable to SBRT receive pembrolizumab IV over 30 minutes on day 1. Patients also receive SBRT in 4 fractions daily on days 2-5 or either IMRT PBRT or 3D-CRT in 15 fractions total concurrent with pembrolizumab administration on days 1-19. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV on day 1 and SBRT on days 44-47 or IMRT PBT or 3D-CRT on days 43-61. Treatment with pembrolizumab repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.|Patients who exhibit a lung lesion of size or location not amenable to SBRT but amenable to WFRT receive pembrolizumab as in Group I and either IMRT PBRT or 3D-CRT in 15 fractions total on days 1-19 concurrent with pembrolizumab administration.|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV as in Group I without XRT. At the first planned efficacy evaluation (5 weeks) patients exhibiting PD are treated with SBRT concurrent with the remaining cycles of pembrolizumab. In the event that lesion size has progressed to the point where the attending physician no longer considers SBRT safe then the patient will be salvaged with IMRT PBRT or 3D-CRT and analyzed as part of the fourth treatment group.|Patients who exhibit a lung lesion with size and location not amenable to SBRT but amenable to WFRT receive pembrolizumab IV as in Group I and IMRT PBRT or 3D-CRT on days 43-61.|Patients who exhibit a lung lesion with size and location not amenable to SBRT but amenable to WFRT receive pembrolizumab IV as in Group I without XRT. The decision on when to start XRT will be assessed first at week 5 (after the second dose of pembrolizumab). If a patient has PD based on irRC then XRT will be delivered after the third dose of pembrolizumab while patients with SD or PR will not start XRT and will continue to be followed. These patients will then have follow up CT scans 5 weeks after course 3 and then approximately every 3 months for the remainder of the trial; any patient at this point with PD will then have XRT delivered with the sixth dose of pembrolizumab.|Patients with lesions amenable to SBRT or WFRT receive pembrolizumab IV as in Group I. Patients also receive either IMRT PBRT or 3D-CRT in 15 fractions to the primary lesions and low dose radiation therapy to other lesions on days 43-61 or SBRT in 4 fractions to primary lesions and low dose radiation therapy to other lesions on days 44-47.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: 3-Dimensional Conformal Radiation Therapy; Other: Laboratory Biomarker Analysis; Radiation: Radiation Therapy; Radiation: Proton Beam Radiation Therapy; Radiation: Stereotactic Body Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Biological: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Disease response according to immune related response criteria (Phase I/II)|Incidence of toxicity (Phase I/II)|Maximum tolerated dose of pembrolizumab and stereotactic body radiation therapy (Phase I)|Maximum tolerated dose of pembrolizumab and non-stereotactic wide-field radiation therapy (Phase I)|Objective response (complete response + partial response) of the non-irradiated disease sites according to Out-Field immune related response criteria (Phase II)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Treatment success will be defined as radiographic complete response or partial response measured using Pearson chi-squared or Fisher exact tests.; Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.; Assesed according to Out-Field immune related response criteria. Treatment success will be defined as radiographic complete response or partial response measured using Pearson chi-squared or Fisher exact tests.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Beginning 3 months after initiation of treatment; Up to 90 days after completion of treatment; 22 days; Up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_42" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>CPL304110 will be administered once daily to adults with advanced solid malignancies in 28-day cycles.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: CPL304110</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD)|Safety profile</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Overall safety profile of CPL304110 as assessed by the type frequency severity timing and relationship to study drug of any adverse events (AEs) serious adverse events (SAEs) and changes in vital signs ECGs and safety laboratory test.; Maximum tolerated dose (MTD) of CPL304110 when administered orally once daily to adults with advanced solid malignancies. The MTD is the highest dose associated with the occurrence of dose-limiting toxicities (DLTs) in 33% of patients.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>First cycle of 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_43" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab; Drug: cis Platinum; Radiation: IMRT; Drug: Paclitaxel; Radiation: SBRT; Drug: Carboplatin; Drug: Etoposide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>12-Month Progression Free Survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival (PFS) will be determined for each subject as a binary variable indicating whether or not the subject is alive and progression free at 12 months</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_44" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose-escalation Phase:||Multiple doses of SY-5007 for oral administration.||Dose Expansion Phase:||RP2D of SY-5007 as determined during Dose Escalation.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SY-5007</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase I: Determine the dose-limiting toxicities (DLT) during the first 28-day cycle of SY-5007 treatment|Phase I: Number of patients with adverse events and serious adverse events|Phase II: Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Characterization of the safety and tolerability; Anti-tumor activity of SY-5007; Maximum Tolerated Dose (MTD) and/or recommended phase 2 dose (RP2D) in Cycle 1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Dose-escalation Cycle 1 (each cycle is 28 days); Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_45" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>CAB-AXL-ADC (BA3011) alone|CAB-AXL-ADC (BA3011) with PD-1 inhibitor</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: CAB-AXL-ADC; Biological: PD-1 inhibitor</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Confirmed Objective Response Rate (ORR) per RECIST v1.1|Incidence of Adverse Events or Serious Adverse Events as assessed by CTCAE v4.03/v5</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Measured by frequency and severity of adverse events as assessed by CTCAE v4.03/v5; Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_46" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Brigatinib 180 mg once daily p.o. with seven day lead-in at 90 mg once daily for 3 years or until progression of disease or unacceptable toxicities or withdrawal of consent|Patients in the control arm will be observational or as per investigators choice patients may receive durvalumab administered within the label in the respective country.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Brigatinib; Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival according to RECIST v1.1 evaluated in the ITT cohort. PFS will be compared between the two arms.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>defined as the time from the date of randomisation until documented progression (according to RECIST v1.1) or death if progression is not documented</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From the date of enrolment until last tumour assessment (approximately 45-48 months after enrolment of the first patient)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_47" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Anlotinib 12mg qd day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles S1 60mg bid day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate or disease progression.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: S1/Anlotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)|progression-free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS will be estimated using standard Kaplan Meier survival analysis methods.; measured by Response Evaluation Criteria in Solid Tumors version 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>each 21 days up to the toxicity or PD (up to 6 months); Duration of time from the start of treatment to the first documented disease progression according to RECIST 1.1 or death due to any cause whichever occurs first assessed up to 12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_48" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>HER2-positive breast cancer HER2-low expressing breast cancer HER2-expressing NSCLC and HER2-mutant NSCLC participants who received escalating doses of DS8201a (initial dose 3.2 mg/kg Q3W) and pembrolizumab 200 mg.|HER2-positive breast cancer participants with prior ado-trastuzumab emtansine (T-DM1) with disease progression and who received DS8201a at the RDE in combination with pembrolizumab 200 mg.|HER2 low breast cancer participants with prior failed standard treatments who received DS8201a at the RDE in combination with pembrolizumab 200 mg.|HER2-expressing NSCLC participants who had not received any prior treatment with anti-PD-1 anti-PD-L1 or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.|HER2-mutant NSCLC participants who had not received any prior treatment with anti-PD-1 anti-PD-L1 or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab; Drug: Trastuzumab deruxtecan (DS-8201a)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose-limiting toxicities (DLTs) Part 1|Objective Response Rate (ORR) Confirmed by Independent Central Review Part 2</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Maximum Tolerated Dose (MTD) or recommended dose expansion (RDE) of DS-8201a (Part1) are based on the occurrence of DLTs.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Within two 3-week cycles (6 weeks); Within approximately 30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_49" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Niraparib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Response Rate (ORR) - Independent Central Review (ICR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To evaluate overall response rate (ORR) as assessed by Independent Central Review (ICR) using RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_50" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Intra-patient dose escalation of intravenous MIDRIXNEO-LUNG autologous DC vaccine</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Control DTH; Biological: Dendritic cell immunotherapy; Biological: Antigen-specific DTH</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety and tolerability of preparing and administrating the autologous dendritic cell-based vaccine in surgically-treated non-small cell lung cancer patients</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Toxicity measures as defined by common toxicity criteria v5.0. The maximal tolerated and/or feasible dose will be defined from the intra-patient dose excalation scheme</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From the day of leukapheresis until 3-4 weeks after the last vaccine dose level i.e. 3 to 5 months depending on the number of doses that can be administered</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_51" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Surufatinib; Drug: Surufatinib Plus Vinorelbine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess the efficacy of Surufatinib or Surufatinib Combined With Vinorelbine for NSCLC  patients by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_52" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Escalating doses followed by expansion targeting HER2-expressing advanced malignancies|Escalating doses followed by expansion targeting HER2-expressing advanced malignancies</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BDC-1001; Drug: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs) and serious adverse events (SAEs)|Incidence and nature of dose-limiting toxicities (DLTs)|Incidence of potential-immune related toxicities|Maximum tolerable dose (MTD) or a tolerated dose below MTD|Objective response rate (ORR) of confirmed complete or partial responses (CR PR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Expansion period; Escalation period</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years; up to 21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_53" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>induction dose 1-4mg/kg of prednisone prednisone 60mg q24h for 2-4wks tapering not faster than 10mg each 14d maintenance dose 10mg q24h for 8wks withdraw of treatment during 4wks summary of treatment time not shorter than 12-24wks.|induction dose 1-4mg/kg of prednisone prednisone 30-60 mg q24h tapering not faster than 10mg each 7d summary of treatment time 6-12wks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Short glucocorticosteroid (prednisone) regimen; Drug: Prolonged glucocorticosteroid (prednisone) regimen</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pneumonitis relapse|Pneumonitis related deaths|Radiological regression of pneumonitis</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Incidence of pneumonitis relapse in study arm A vs. control arm B; Computed tomography assesment of pneumonitis regression compared to initial examination. 4-point scale: coplete regression definite partial response slight partial response progression.; Incidence of pneumonitis related deaths in arm A vs. arm B</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 weeks and 52 weeks; 12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_54" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab + Regorafenib Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Phase 1 : Avelumab; Drug: Phase 2 : Regorafenib; Drug: Phase 2: low-dose Regorafenib; Drug: Phase 1 : Regorafenib; Drug: Phase 2 : Avelumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>PHASE I : Recommended phase II dose (RP2D)|PHASE II (7 phase II cohorts) : Assessment of the antitumor activity of regorafenib|Phase II (cohort H and I): Assessment of the antitumor activity of regorafenib|Phase II (cohort A'): Assessment of the antitumor activity of regorafenib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab based on 6-month progression-free rate defined as CR PR and SD following RECIST v1.1 criteria.; Recommended phase II dose (RP2D) evaluated on the first cycle (Day 1 to Day 28) of regorafenib when prescribed in association with avelumab.; Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab based on objective response under treatment defined as CR or PR following RECIST v1.1 criteria.; Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab based on 4-months progression-free rate defined as CR PR and SD following RECIST v1.1 criteria.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>During the first cycle (28 days); Throughout the treatment period an average of 6 months; 6 months; 4 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_55" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Group 1(n = 5) healthy volunteers. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).|Group2 (n = 5) newly diagnosed lung cancer. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).|Group 3 (n = 10) lung cancer after non-surgical therapy. Each participant in this part of the study will receive a total of 2 doses of [18F]-C-SNAT4 (on 2 separate occasions spaced at least 1 week apart each of which will be followed by undergoing a [18F]-C-SNAT4 PET/CT scan)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: 18F-C-SNAT4; Procedure: Positron emission tomography (PET)/Computed tomography (CT) Scan</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Biodistribution of [18F]-C-SNAT4</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Whole-body [18F]-C-SNAT4 PET scans will be performed at 60 min post intravenous injection of the PET tracer in Group 1 of 5 healthy volunteers</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>1 day</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_56" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>In Part 1 dose escalation patients will receive EMB-01 IV once weekly and osimertinib PO QD on days 1-28. The treatment cycle repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.||In Part 2 dose expansion patients will receive EMB-01 IV once weekly and osimertinib PO QD on days 1-28 at the recommended phase II dose (RP2D) regimen. The treatment cycle repeats every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Osimertinib; Drug: EMB-01</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD) of EMB-01 and osimertinib (Phase Ib only)|Rate of Adverse Events (AE) and Serious Adverse Events (SAE)|Recommended phase II dose (RP2D) of EMB-01 and osimertinib (Phase Ib)|Objective Response Rate (ORR) (Phase II only)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Objective response rate measured by RECIST 1.1; Adverse events and serious adverse events as assessed by CTCAE v5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From first dose until the date of first documented progression or date of death from any cause whichever comes first up to 2 years; From enrollment up to 30 days after the last dose; Up to 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_57" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive PF-07799544|Participants will receive PF-07799544 and PF-07284890|Participants will receive PF-07799544|Participants will receive PF-07799544 and PF-07284890|Participants will receive PF-07799544 and PF-07799933|Participants will receive PF-07799544 and PF-07799933</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: encorafenib; Drug: PF-07799933; Drug: PF-07284890; Drug: PF-07799544</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with dose limiting toxicities (DLTs) Phase 1a monotherapy and Phase 1b combination therapy dose escalation|Overall response rate (ORR) (phase 1b expansion)|Number of participants with treatment-emergent adverse events (AEs) (phase 1a and 1b dose escalation phases)|Number of participants with clinically significant change from baseline in laboratory abnormalities (phase 1a and phase 1b dose escalation phase)|Number of participants with clinically significant change from baseline in vital sign abnormalities (phase 1a and phase 1b dose escalation phase)|Number of participants with clinically significant change from baseline in physical exam abnormalities (phase 1a and phase 1b dose escalation phase)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>AEs as characterized by type frequency severity timing seriousness and relationship to study therapy; Laboratory abnormalities as characterized by type frequency severity and timing.; Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); Physical exam abnormalities as as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.; DLTs will be evaluated during the first cycle (21 days) as a single agent (phase 1a monotherapy) or in combination with other agents (phase 1b dose escalation); Vital sign abnormalities as characterized by type frequency severity and timing.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline to 28 days after last dose of study treatment; Cycle 1 (21 days); Baseline to 2 years; Baseline to 28 days after last dose of study medication</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_58" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Monotherapy dose escalation of PF-07284890|Combination dose escalation of PF-07284890 + binimetinib|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma with asymptomatic brain involvement and no prior BRAF or MEK inhibitor utilization|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma with symptomatic brain involvement and no prior BRAF or MEK inhibitor utilization|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma with asymptomatic brain involvement and prior BRAF inhibitor utilization|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma with symptomatic brain involvement and prior BRAF inhibitor utilization|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 solid tumor; history of or current leptomeningeal metastases; without disease in the brain; with disease in the brain that does not meet Cohorts 1-4; asymptomatic or symptomatic in the brain; primary brain tumors|PF-07284890 (at recommended dose from Part A) plus binimetinib plus midazolam in participants with BRAF V600 solid tumor|PF-07284890 (at the recommended dose for expansion when administered with food) plus binimetinib in participants with BRAF V600 solid tumor</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Midazolam; Drug: PF-07284890; Drug: Binimetinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1a - Number of participants with dose limiting toxicities (DLTs)|Phase 1a - Number of participants with treatment emergent adverse events (AEs)|Phase 1a - Number of participants with clinically significant change from baseline in laboratory abnormalities|Phase 1a - Number of dose interruptions dose modifications and discontinuations due to AEs|Phase 1b - Overall response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>AEs as characterized by type frequency severity timing seriousness and relationship to study therapy; Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and intracranial response by modified RECIST version 1.1 (mRECIST v 1.1) or RANO for primary brain tumors; DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with binimetinib. The number of DLTs will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study; Incidence of dose interruptions dose modifications and discontinuations due to AEs; Laboratory abnormalities as characterized by type frequency severity and timing</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 (approximately 21 days / 3 weeks); Baseline up to follow up visit (30 days after last dose of study treatment); Baseline through approximately 12 months; Baseline up to approximately 12 months; Baseline up to 30 days after last dose of study medication</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_59" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>metastatic Melanoma (mM) metastatic Urothelial Carcinoma (mUC) and advanced Heptocellular Carcinoma (HCC)|metastatic Melanoma (mM)|metastatic non small cell lung cancer (NSCLC)|advanced or metastatic renal cell carcinoma (RCC)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ipilimumab; Drug: nivolumab; Drug: ENHANZE (rHuPH20)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1 Arm A: Average concentration of ipilimumab (Cavg21d)|Part 1 Arm A: Area under the concentration in ipilimumab AUC(0-21d)|Part 1 Arm A: Maximum observed serum concentration of ipilimumab (Cmax)|Part 1 Arm A: Observed concentration of ipilimumab at 21 days post dose (C21d)|Part 1 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)|Part 2 Arm A: Average concentration in ipilimumab (Cavg42d)|Part 2 Arm A: Area under the concentration in ipilimumab AUC(0-42d)|Part 2 Arm A: Maximum observed serum Concentration of Ipilimumab (Cmax)|Part 2 Arm A: Observed concentration in ipilimumab (C42d)|Part 2 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)|Part 2 Arm B: Average concentration of Ipilimumab at 21 days post dose (Cavg21d)|Part 2 Arm B: Area Under the Concentration in Ipilimumab AUC(0-21d)|Part 2 Arm B: Maximum observed serum Concentration in Ipilimumab (Cmax)|Part 2 Arm B: Observed concentration of ipilimumab at 21 days post dose (C21d)|Part 2 Arm B: Time of maximum observed concentration in Ipilimumab (Tmax)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 21; Up to 42 days; Up to 21 days; Day 42</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_60" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive the low dose of Tarlatamab.|Participants will receive the high dose of Tarlatamab.|Participants will receive the selected target dose of Tarlatamab based on findings in Part 1.|Participants will receive the selected target dose of Tarlatamab based on findings in Part 1 with reduced Cycle 1 monitoring requirements.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Tarlatamab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator|Part 1 and Part 3 Only: Number of Participants who Experience One or More Treatment-emergent Adverse Events|Part 1 Only: Serum Concentrations of Tarlatamab|Part 1 and Part 2 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to a maximum of 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_61" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with SCLC CRPC and FL will receive PF-06821497 at escalating dose levels|Participants with FL will receive PF-06821497 at escalating dose levels|Participants with CRPC will receive PF-06821497 at escalating dose levels.|Participants with CRPC and SCLC will receive PF-06821497 at escalating dose levels in combination with SOC.|Participants with CRPC will receive PF-06821497 in combination with SOC or SOC alone.|Participants with CRPC will receive PF-06821497 at one or two doses|Participants will receive PF-06821497 at one or two doses</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: PF-06821497</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)|Overall safety profile including adverse events|Preliminary efficacy determination as evaluated by disease specific response criteria|Overall safety profile including laboratory abnormalities|Overall safety profile including vital signs</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Laboratory abnormalities as characterized by type frequency severity (as graded by NCI CTCAE version [4.03]) and timing.; Vital sign changes from baseline including blood pressure heart rate ECG changes.; First cycle DLTs will be utilized to determine the MTD; Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]); Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline up to approximately 2 years; Through study completion approximately 2 years past last patient first visit.; Baseline up to 90 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_62" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>PF-07248144 Monotherapy Escalation|PF-07248144 with Fulvestrant Combination Dose Escalation|PF-07248144 with Letrozole + Palbociclib Combination Dose Escalation|PF-07248144 Monotherapy Dose Expansion|PF-07248144 with Fulvestrant Dose Expansion|PF-07248144 with PF-07220060 +Fulvestrant|PF-07248144 with PF-07220060 +Fulvestrant Dose Expansion|PF-07248144 Monotherapy Dose Expansion</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Letrozole; Drug: PF-07220060; Drug: PF-07248144; Drug: Palbociclib; Drug: Fulvestrant</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with dose-limiting toxicities in the Dose Escalation Arms.|Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms.|Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms.|Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion Arms|Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion Arms</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Dose-limiting toxicities (DLTs); Laboratory abnormalities as characterized by type frequency severity (as graded by NCI CTCAE version 5.0) and timing.; Adverse Events as characterized by type frequency severity (as graded by NCI CTCAE version 5.0) timing seriousness and relationship to study therapy.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months; Up to 29 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_63" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Once daily tablet 80 mg</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AZD9291</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): = 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (according to independent review) that was confirmed at least 4 weeks later prior to progression or further anti-cancer therapy.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>RECIST tumour assessments every 6 weeks from first dose until objective disease progression up to approximately 11 months (at the time of analysis)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_64" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>LY3537982 administered orally.|LY3537982 administered orally either alone or with another investigational agent.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: LY3295668; Drug: LY3537982; Drug: Pemetrexed; Drug: Carboplatin; Drug: Pembrolizumab; Drug: Cetuximab; Drug: Cisplatin; Drug: Abemaciclib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy|Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents|Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-nave participants with advanced NSCLC in combination with pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Measured by TEAEs; Measured by the number of patients with dose-limiting toxicities (DLTs)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Estimated up to 2 years; Cycle 1 (21 Days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_65" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with solid non-small cell lung cancer (NSCLC) harboring NTRK fusions (arm closed)|Patients with solid thyroid tumors harboring NTRK fusions (arm closed)|Patients with soft-tissue sarcoma harboring NTRK fusions (arm closed)|Patients with solid colorectal tumors harboring NTRK fusions (arm closed)|Patients with solid salivary tumors harboring NTRK fusions (arm closed)|Patients with solid biliary tumors harboring NTRK fusions (arm closed)|Patients with solid tumors in the primary central nervous system (CNS) harboring NTRK fusions (arm closed)|Patients with e.g. kidney cancer squamous cell cancer of head or neck or ovarian solid tumors harboring NTRK fusions (arm closed)|Patients eligible for arms 1 to 8 but with documented NTRK fusion from a laboratory where CLIA or equivalent certification cannot be confirmed by the sponsor at the time of consent (arm closed)|Patients with melanoma non secretory breast and colorectal cancer or other tumor types harboring NTRK fusions except soft tissue sarcoma salivary gland and thyroid cancer (closed)|Patients with all tumor types harboring NTRK fusions not eligible for the main prospective cohort including patients with non-measurable disease</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BAY2757556 (Larotrectinib Vitrakvi)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Best overall response rate by IRC</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Proportion of subjects with either complete response or partial response as determined by an independent radiology committee (IRC) using RECIST or RANO criteria.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 120 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IT ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_it">New Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Advanced inoperable squamous cell carcinomas of the head and neck</td>
    <td>Replimune Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_66">Study Arms</button></td>
    <td><p>RP3; CCRT(concurrent chemoradiation therapy); carboplatin and paclitaxel; nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_536">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05743270" target="_blank">NCT05743270</a></td><td><select class="form-select" id="select_form_73" name="NCT05743270"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Newly Diagnosed MGMT Unmethylated Glioblastoma</td>
    <td>Darell Bigner</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_67">Study Arms</button></td>
    <td>D2C7-IT; 2141-V11</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05734560" target="_blank">NCT05734560</a></td><td><select class="form-select" id="select_form_74" name="NCT05734560"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo4" class="accordion-toggle">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_66" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>RP3 will be administered via direct intratumoral injection or via CT ultrasound or laryngoscopy guided intratumoral injection into superficial subcutaneous (SC) or nodal lesions and into deeper lesions including visceral lesions.|standard-of-care CCRT (defined as intensity-modulated radiation therapy [IMRT] and cisplatin|RP3 will be administered via direct intratumoral injection or via CT ultrasound or laryngoscopy guided intratumoral injection into superficial subcutaneous (SC) or nodal lesions and into deeper lesions including visceral lesions.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: nivolumab; Other: carboplatin and paclitaxel; Biological: RP3; Other: CCRT(concurrent chemoradiation therapy)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>LA Cohort: Progression-free Survival|R/M Cohort: Objective Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival is defined as the time from the first day of study treatment to the date of progression of disease which was subsequently confirmed or death by any cause whichever occurs first; Percentage of subjects achieving objective response (complete response + partial response)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From Day 1 to documented progression of disease (up to 3 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_67" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Single D2C7-IT intratumoral infusion (6920 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours followed by an injection of 2141-V11 in the cervical perilymphatic subcutaneous area ipsilateral to the tumor at week 2 radiation and further injections of 2141-V11 in the cervical perilymphatic subcutaneous area ipsilateral to the tumor.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: D2C7-IT; Drug: 2141-V11</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Median survival defined as the time between initiation of treatment with D2C7-IT in combination with 2141-V11 and death or last follow up if alive.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_it">Existing Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Trial terminated</strong></td>
    <td>Squamous cell carcinoma of the head and neck</td>
    <td>Celgene</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_68">Study Arms</button></td>
    <td><p>VTX-2337; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_538">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03906526" target="_blank">NCT03906526</a></td><td><select class="form-select" id="select_form_75" name="NCT03906526"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Micro satellite-stable (MSS) colorectal or gastroesophageal cancer metastatic to liver or advanced ovarian cancer</td>
    <td>ImmVirx Pty Ltd</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_69">Study Arms</button></td>
    <td>IVX037</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05427487" target="_blank">NCT05427487</a></td><td><select class="form-select" id="select_form_76" name="NCT05427487"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Advanced Head and Neck Squamous Cell Carcinoma; Advanced Breast Cancer; Advanced Melanoma</td>
    <td>Cytovation AS</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_70">Study Arms</button></td>
    <td><p>CyPep-1; Pembrolizumab 25 MG/ML [Keytruda]</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05383170" target="_blank">NCT05383170</a></td><td><select class="form-select" id="select_form_77" name="NCT05383170"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 104 days</strong></td>
    <td>Cervical cancer that has come back remains despite treatment or has spread to other places in the body</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_71">Study Arms</button></td>
    <td><p>Atezolizumab; Bevacizumab; Laboratory Biomarker Analysis</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02921269" target="_blank">NCT02921269</a></td><td><select class="form-select" id="select_form_78" name="NCT02921269"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Histologically confirmed diagnosis of solid tumor and/or its metastases</td>
    <td>Gene Surgery LLC</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_72">Study Arms</button></td>
    <td><p>Intratumoral administration of Stimotimagene copolymerplasmid; Intravenous administration of Ganciclovir (Cymeven)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05578820" target="_blank">NCT05578820</a></td><td><select class="form-select" id="select_form_79" name="NCT05578820"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 151 days</strong></td>
    <td>Cervical Cancer</td>
    <td>Kortuc Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_73">Study Arms</button></td>
    <td><p>KRC-01; External Beam Radiation Therapy; cisplatin; brachytherapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05570422" target="_blank">NCT05570422</a></td><td><select class="form-select" id="select_form_80" name="NCT05570422"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo5" class="accordion-toggle">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_68" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Nivolumab IV every 2 weeks|Motolimod IT injection weekly|Nivolumab IV every 2 weeks and Motolimod IT injection weekly|Nivolumab IV every 2 weeks and Motolimod SC injection weekly</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: VTX-2337; Drug: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Numbers of CD8+ T cells within the tumor pre-treatment and post-surgery</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Tumor immune modulation will be evaluated by counting the number of tumor infiltration CD8+ T cells before and after treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Screening through Study Day 52</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_69" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>IVX037 administered intratumorally 1 2 or 3 doses q2wks Day 1 15 and 29 of Cycle 1.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: IVX037</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of dose-limiting toxicities</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assess the feasibility safety and tolerability of intratumoral IVX037 when administered to patients with advanced colorectal ovarian or gastric cancers.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>21 days after following cessation of study intervention</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_70" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic HNSCC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic melanoma. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic TNBC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab 25 MG/ML [Keytruda]; Drug: CyPep-1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence frequency and seriousness of TEAEs|Incidence of DLTs|ORR based on radiological assessment according to the RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 weeks; 6 weeks; 8 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_71" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Bevacizumab; Drug: Atezolizumab; Other: Laboratory Biomarker Analysis</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants With Objective Response Rate (ORR Either Partial or Complete Response) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Complete Response (CR) is the disappearance of all lesions and Partial Response is at least a 30% decrease in the sum of the diameters of target lesions taking as reference the baseline sum diameters. Overall Response (OR) is CR+PR.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_72" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Stimotimagene copolymerplasmid will be administered intratumoral once in a dose of 20 mkg of DNA per 1 cm3 of tumor (for cohort 1) and 40 mkg of DNA per 1 cm3 of tumor (for cohort 2).||Ganciclovir (Cimeven) will be administrated intravenous twice a day at 12-hour intervals for 15 days.|Stimotimagene copolymerplasmid will be administered intratumorally twice with 5-day interval in the optimal dose selected at previous stage of the trial.||Ganciclovir (Cimeven) will be administrated intravenous twice a day at 12-hour intervals for 15 days.|Stimotimagene copolymerplasmid will be administered intratumorally three times with 5-day interval in the optimal dose selected at first stage of the trial.||Ganciclovir (Cimeven) will be administrated intravenous twice a day at 12-hour intervals for 15 days.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Intravenous administration of Ganciclovir (Cymeven); Biological: Intratumoral administration of Stimotimagene copolymerplasmid</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety (Presence/absence of dose-limiting toxicities (DLTs))|Safety (Frequency and severity of adverse events (CTCAE classification))|Safety (Number of cases of early termination of participation in the study due to the development of Serious Adverse Events and Other Adverse Events associated with the study therapy)|Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients' peripheral blood)|Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients' urine)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Day -1 (baseline) Day 1 (4 h and 8 h after drug administration) Day 2 (24 h after drug administration) Day 3 (48 h after drug administration) Days 5 7 12 17 25 303 605 907 1303 for patients from 1st step of the study; Day -1 (baseline) Day 1 (4 h and 8 h after drug administration) Day 2 (24 h after drug administration) Day 3 (48 h after drug administration) Day 6 (before drug administration and 8 h after drug administration) Days 7 12 17 25 303 605 907 1303 for patients from 2nd step of the study; Day -1 (baseline) Day 1 (4 h and 8 h after drug administration) Day 2 (24 h after drug administration) Day 3 (48 h after drug administration) Day 6 (before drug administration and 8 h after drug administration) Day 7 Day 11 (before drug administration and 8 h after drug administration) Days 12 17 25 303 605 907 1303 for patients from 3rd step of the; Assessment of quantitative content of plasmid DNA (pTKhGM) in patients' peripheral blood at:; Assessment of presence/absence of dose-limiting toxicities (DLTs); Assessment of frequency and severity of adverse events (CTCAE classification); Day -1 (baseline) Day 1 (4 h and 8 h after drug administration) Day 2 (24 h after drug administration) Day 3 (48 h after drug administration) Days 5 7 12 17 25 303 605 907 1303 for patients from 1st step of the study; Day -1 (baseline) Day 1 (4 h and 8 h after drug administration) Day 2 (24 h after drug administration) Day 3 (48 h after drug administration) Day 6 (before drug administration and 8 h after drug administration) Days 7 12 17 25 303 605 907 1303 for patients from 2nd step of the study; Day -1 (baseline) Day 1 (4 h and 8 h after drug administration) Day 2 (24 h after drug administration) Day 3 (48 h after drug administration) Day 6 (before drug administration and 8 h after drug administration) Day 7 Day 11 (before drug administration and 8 h after drug administration) Days 12 17 25 303 605 907 1303 for patients from 3rd step of the study.; Assessment of quantitative content of plasmid DNA (pTKhGM) in patients' urine at:; Assessment of number of cases of early termination of participation in the study due to the development of Serious Adverse Events and Other Adverse Events associated with the study therapy)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through study completion an average of 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_73" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose-escalation single arm open label study. All eligible subjects will receive external beam radiotherapy (EBRT) with cisplatin (40 mg/m2) intravenously (IV) once weekly for 5 weeks (sixth dose optional) followed by image-guided brachytherapy (BT).||KRC-01 will be dosed intratumorally within 2 hours prior to EBRT starting from second week of EBRT.||There are two cohorts (n=5 per cohort) Cohort 1: Once-a-week between Monday to Thursday (not necessarily the same day every week) Cohort 2: Twice-a-week with a 1- or 2- day interval (either Mon+Wed Mon+Thu or Tue+Thu)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: KRC-01; Radiation: External Beam Radiation Therapy; Drug: cisplatin; Radiation: brachytherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Adverse Events|AEs of special interest|Physical examination|Tolerance</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Head eyes ears nose and throat; Abdomen; Extremities; Dermatologic; General appearance; An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a study drug that does not necessarily have a causal relationship with the treatment.;  Number of patients who have a significant treatment delays/interruption (total duration  59 days); Lymphatic Partial examination patient will verbally report changes since last week.; Respiratory; Musculoskeletal; The physical examination will include:; Cardiovascular; Neurologic; (local pain radiation dermatitis tumor lysis syndrome superficial soft tissue fibrosis vaginal stenosis gastrointestinal/urinary AEs and severe and medically significant bleeding (requires urgent intervention) after intratumoral injection)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>at the time of Screening and at Week 6 and partial examination will be done weekly in between to document relevant changes.; 36 month; week 1 to 6</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW  CT ########### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ct">New Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Advanced Urothelial Carcinoma</td>
    <td>University Hospital Inselspital Berne</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_74">Study Arms</button></td>
    <td><p>Magrolimab; Cisplatin; Gemcitabine</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05738161" target="_blank">NCT05738161</a></td><td><select class="form-select" id="select_form_81" name="NCT05738161"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo6" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_74" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Magrolimab therapy in combination with standard first line platinum-based chemotherapy (with Cisplatin / Gemcitabine) in advanced urothelial carcinoma.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Magrolimab; Drug: Gemcitabine; Drug: Cisplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Limiting Toxicity in Run-in Phase|Proportion of participants with any AEs of severity grade 3 or higher</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Proportion of participants with any AEs of severity grade 3 or higher according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 over 6 months after IMP dose initiation; Incidence of DLTs in participants of the safety run-in phase</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 6 months after IMP dose initiation; End of cycle 1 (day 21)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING CT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ct">Existing Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date now September 30 2023</strong></td>
    <td>Solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory)</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_75">Study Arms</button></td>
    <td><p>Ipilimumab; Laboratory Biomarker Analysis; Nivolumab; Pharmacological Study</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02304458" target="_blank">NCT02304458</a></td><td><select class="form-select" id="select_form_82" name="NCT02304458"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from suspended to active</strong></td>
    <td>Poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back after a period of improvement (relapsed) or has not responded to treatment (refractory)</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_76">Study Arms</button></td>
    <td><p>Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration and Biopsy; Ipilimumab; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02879695" target="_blank">NCT02879695</a></td><td><select class="form-select" id="select_form_83" name="NCT02879695"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 236</strong></td>
    <td>Esophageal and gastroesophageal junction adenocarcinoma</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2|Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_77">Study Arms</button></td>
    <td><p>Carboplatin; Computed Tomography; Ipilimumab; Nivolumab; Paclitaxel; Positron Emission Tomography; Radiation Therapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03604991" target="_blank">NCT03604991</a></td><td><select class="form-select" id="select_form_84" name="NCT03604991"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Epithelial ovarian primary peritoneal or fallopian tube cancer that has not responded after prior treatment (persistent) or has come back (recurrent)</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_78">Study Arms</button></td>
    <td><p>Ipilimumab; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02498600" target="_blank">NCT02498600</a></td><td><select class="form-select" id="select_form_85" name="NCT02498600"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Metastatic or refractory anal canal cancer</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_79">Study Arms</button></td>
    <td><p>Biospecimen Collection; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02314169" target="_blank">NCT02314169</a></td><td><select class="form-select" id="select_form_86" name="NCT02314169"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 845 days</strong></td>
    <td>Esophageal or esophageal/gastroesophageal junction cancer that has not spread to other places in the body (non-metastatic)</td>
    <td>City of Hope Medical Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_80">Study Arms</button></td>
    <td><p>Carboplatin; Endoscopic Biopsy; External Beam Radiation Therapy; Lenvatinib Mesylate; Paclitaxel; Pembrolizumab; Resection</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04929392" target="_blank">NCT04929392</a></td><td><select class="form-select" id="select_form_87" name="NCT04929392"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 122 days; Primary Completion Date pushed later by 92 days</strong></td>
    <td>Circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II III or IV</td>
    <td>Enterome</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_81">Study Arms</button></td>
    <td>EO2040</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05350501" target="_blank">NCT05350501</a></td><td><select class="form-select" id="select_form_88" name="NCT05350501"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 346 days; Primary Completion Date pushed later by 310 days</strong></td>
    <td>Idiopathic Thrombocytopenic Purpura</td>
    <td>AO GENERIUM</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_82">Study Arms</button></td>
    <td>GNR-069; Nplate</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05220878" target="_blank">NCT05220878</a></td><td><select class="form-select" id="select_form_89" name="NCT05220878"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 366 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT) renal transplantation and chemotherapy</td>
    <td>Children's Hospital of Philadelphia</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_83">Study Arms</button></td>
    <td>BK-virus specific CTLs</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04293042" target="_blank">NCT04293042</a></td><td><select class="form-select" id="select_form_90" name="NCT04293042"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 510 days</strong></td>
    <td>Metastatic/unresectable solid tumors; Metastatic HER2-negative breast cancer</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_84">Study Arms</button></td>
    <td><p>Entinostat; Ipilimumab; Nivolumab; Pharmacogenomic Study; Pharmacological Study</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_543">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02453620" target="_blank">NCT02453620</a></td><td><select class="form-select" id="select_form_91" name="NCT02453620"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Primary Completion Date pushed later by 731 days</strong></td>
    <td>Multiple Myeloma monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM)</td>
    <td>Baylor College of Medicine</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_85">Study Arms</button></td>
    <td>TAA-specific CTLs; TAA-specific CTLs- fixed dose</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02291848" target="_blank">NCT02291848</a></td><td><select class="form-select" id="select_form_92" name="NCT02291848"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo7" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_75" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>See Detailed Description</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Biological: Ipilimumab; Other: Pharmacological Study</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab|Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The frequency (%) of patients experiencing a dose limiting toxicity at least possibly attributable to nivolumab as a single agent or in combination with ipilimumab by study part and dose level.; Frequency of disease response (best overall response of partial or complete response) assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR) Disappearance of all target lesions; Partial Response (PR) =30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR by study part and dose level.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 days; Up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_76" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes on day 11 and then every 2 weeks for up to year. Some patients also receive ipilimumab IV over 90 minutes on day 11 and then every 6 weeks for up to 1 year. Patients also undergo bone marrow aspiration and biopsy and blood sample collection throughout the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration and Biopsy; Biological: Nivolumab; Biological: Ipilimumab; Biological: Blinatumomab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events|Maximum tolerated dose</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Maximum tolerated dose will be defined as the maximum dose level in the absence of dose limiting toxicity in each patient assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The maximum tolerated dose of the combination of blinatumomab plus nivolumab and blinatumomab plus both nivolumab and ipilimumab will be determined in subjects with poor-risk relapsed or refractory CD19+ Pre-B cell acute lymphoblastic leukemia or CD19+ mixed phenotype acute leukemia.; Incidence of adverse events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. All adverse events and toxicities will be tabulated and reported by type and grade for all dose levels of all treatment combinations and the proportions reported with exact 95% binomial confidence intervals.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_77" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive carboplatin IV and paclitaxel IV once weekly and undergo radiation therapy QD (Monday-Friday) beginning on day 1 of each cycle. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or PET scan during screening and follow-up.|Patients receive carboplatin paclitaxel and radiation therapy as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or PET scan during screening and follow-up.|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan throughout the trial.|Patients receive nivolumab as in Arm C and receive ipilimumab IV over 90 minutes on day 1 of cycles 1 and 4 and day 15 of cycles 2 and 5. Treatment repeats every 4 weeks for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan throughout the trial.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Positron Emission Tomography; Drug: Paclitaxel; Drug: Carboplatin; Biological: Nivolumab; Biological: Ipilimumab; Radiation: Radiation Therapy; Procedure: Computed Tomography</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pathologic complete response (Step I)|Disease-free survival (DFS) (Step 2)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DFS measured from the adjuvant treatment randomization will be the endpoint of the adjuvant portion of the study and to achieve the desired power it is expected that patients will be followed for an additional year post completion of accrual to the adjuvant portion. The DFS comparison will be between patients randomized to Arm C (nivolumab) versus Arm D (nivolumab plus ipilimumab) using a one-sided 0.10 level stratified log rank test.; The study with compare the pathologic complete response of Arm A and Arm B using a one-sided 0.10 level chi-squared test for proportions.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 5 weeks; From the adjuvant treatment randomization assessed for up to 7 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_78" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>INDUCTION: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.||MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity.|INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.||MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Nivolumab; Biological: Ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Tumor Response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Complete and Partial Tumor Response by modified irRECIST. Per Response Evaluation Criteria In Solid Tumors Criteria (irRECIST) for target lesions and assessed by MRI: Complete Response (CR) Disappearance of all target lesions; Partial Response (PR) =30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Within 6 months of study entry</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_79" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive nivolumab IV over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan MRI and blood sample collection throughout the study.|Patients receive nivolumab IV over 30 minutes once every 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan MRI and blood sample collection throughout the study.|Patients receive nivolumab as in Arm I. Patients also receive ipilimumab IV over 30 minutes once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan MRI and blood sample collection throughout the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Magnetic Resonance Imaging; Procedure: Biospecimen Collection; Biological: Nivolumab; Biological: Ipilimumab; Procedure: Computed Tomography</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall response rate: number of participants with response (Part A)|Progression-free survival (PFS) (Part B)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Responses assessed using computed tomography (CT) scans or magnetic resonance imaging according to standard Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria in order to assess disease progression. Complete Response (CR): Disappearance all target lesions; any pathological lymph nodes reduction in short axis to  10 mm ( 1 cm). Partial Response (PR):  30% decrease in sum diameters of target lesions. Progressive Disease (PD):  20% increase in sum diameters lesions. (Note: appearance of one or  new lesions considered progressions). Stable Disease (SD): Neither shrinkage qualify for PR nor increase for PD.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years; Time period from the date of randomization to the date of PD or death whichever occurred first assessed up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_80" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>CHEMORADIATION PHASE: Patients receive carboplatin IV and paclitaxel IV QW for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT over 6 weeks and receive pembrolizumab IV over 30 minutes on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity.||WINDOW PERIOD: Patients receive pembrolizumab IV over 30 minutes on day 1 of week 3 and lenvatinib mesylate PO QD at weeks 3-6 in the absence of disease progression or unacceptable toxicity.||SURGERY/SURVEILLANCE: Patients without complete response undergo standard of care surgical resection. Patients with complete response/pursue non-operative management undergo surveillance via periodic endoscopic biopsy.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Endoscopic Biopsy; Procedure: Resection; Drug: Paclitaxel; Drug: Carboplatin; Drug: Lenvatinib Mesylate; Radiation: External Beam Radiation Therapy; Biological: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pathological complete response (CR)|Clinical complete response (CR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Defined as no radiographic evidence of disease on positron emission tomography /computed tomography or CT imaging. Clinical CR rate will be estimated by the proportion of patients achieving clinical CR along with the 95% exact binomial confidence interval.; Defined as no residual cancer cells including lymph nodes under pathologic examination of the surgically resected specimen and/or a Tumor Regression Score of 0 by the College of American Pathologist (CAP) Cancer Protocol for Esophageal Carcinoma. Pathological CR rate will be estimated by the proportion of patients achieving pathological CR along with the 95% exact binomial confidence interval.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At 14 weeks after starting protocol chemoradiotherapy</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_81" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients With Circulating Tumor DNA-defined Minimal Residual Disease of Colorectal Cancer Stage II III or IV After Completion of Curative Therapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: EO2040</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Response to treatment at 6 months</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Percentage of patients with ctDNA clearance and no radiographic evidence of recurrence</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_82" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Main group (80 patients) - multiple weekly subcutaneous injections of GNR-069 doses are calculated individually.|Control group (80 patients) - multiple weekly subcutaneous injections of Nplate doses are calculated individually.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: GNR-069; Biological: Nplate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Proportion of patients achieving sustained response to treatment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A sustained response to treatment is defined as the number of platelets  50.0 x 109/L for at least 9 out of 12 consecutive visits during the treatment period with the study or reference drug.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>26 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_83" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>All patients with symptoms that are consistent with BK cystitis and/or nephropathy (frequency dysuria hematuria elevated creatinine) will have serum quantitative DNA PCR for BK virus level measured in log copies per mL (results also expressed in copies per milliliter) performed in the Children's Hospital of Philadelphia Infectious Disease Diagnostics Laboratory</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: BK-virus specific CTLs</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with Grade III-IV acute GVHD|Number of patients with undetectable BK viral load</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of participants with Grade III-IV acute GVHD as assessed by CTCAE v4.0; Number of patients with undetectable BK viral load as measured by qPCR</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 8 weeks after last BK-CTL infusion; 12 weeks after first BK-CTL infusion</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_84" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive entinostat PO on days -14 and -7 and then weekly nivolumab IV over 60 minutes on day 1 and then every 2 weeks and ipilimumab IV over 90 minutes on day 1 and then every 6 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Nivolumab; Biological: Ipilimumab; Drug: Entinostat; Other: Pharmacogenomic Study; Other: Pharmacological Study</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Graded per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. Safety and tolerability will be analyzed through the incidence of adverse events serious adverse events and specific laboratory abnormalities (worst grade) in each arm. Toxicities will be tabulated by type and grade for all doses and presented using frequencies and percentages based on the CTCAE v5.0. The proportion of dose-limiting toxicities at each dose level will be reported with exact 95% confidence intervals.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 100 days after last dose of nivolumab</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_85" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receiving TAA-specific CTLs as therapy for Myeloma|Patients receiving TAA-Specific CTLs as adjunctive therapy following autologous or syngeneic transplant for myeloma|Patients with high risk MGUS or smoldering myeloma receiving a fixed dose TAA-Specific CTLs</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: TAA-specific CTLs- fixed dose; Biological: TAA-specific CTLs</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Patients with Adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To determine the safety of 2 intravenous injections of autologous TAA-specific cytotoxic T-lymphocytes (CTL) in patients with Myeloma as well as those with high risk MGUS/Smoldering myeloma.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>8 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IA ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ia">New Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Newly diagnosed MGMT promoter unmethylated glioblastoma</td>
    <td>Washington University School of Medicine</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_86">Study Arms</button></td>
    <td>Personalized Neoantigen DNA vaccine; Retifanlimab; TDS-IM v 2.0 electroporation device</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05743595" target="_blank">NCT05743595</a></td><td><select class="form-select" id="select_form_93" name="NCT05743595"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo8" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_86" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cohort A will receive the personalized neoantigen DNA vaccine via electroporation mediated IM injection alone during the first two priming doses then concurrently with retifanlimab during the subsequent boosting doses (Doses 3 through 6)|The personalized neoantigen DNA vaccine will be given once every 28 days for up to 6 doses. Retifanlimab is given at a fixed dose of 500 mg every 28 days.|Patients may receive up to 6 doses of personalized neoantigen DNA vaccine and up to 12 months total of retifanlimab|Cohort B will receive the personalized neoantigen DNA vaccine via electroporation mediated IM injection plus concurrent retifanlimab beginning with Dose 1 and continuing for a total of 6 doses.|The personalized neoantigen DNA vaccine will be given once every 28 days for up to 6 doses. Retifanlimab is given at a fixed dose of 500 mg every 28 days.|Patients may receive up to 6 doses of personalized neoantigen DNA vaccine and up to 12 months total of retifanlimab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Device: TDS-IM v 2.0 electroporation device; Biological: Personalized Neoantigen DNA vaccine; Biological: Retifanlimab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety as measured by treatment-related dose-limiting toxicity (DLT) rate related to vaccination</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The DLT observation period begins with date of first vaccine administration and continues for 30 days from administration of first dose of retifanlimab. For patients in Cohort A this is Day 87 (first dose of retifanlimab is given with vaccine Dose 3 on Day 57) and for patients in Cohort B this is Day 30 (first dose of retifanlimab is given with vaccine Dose 1 on Day 1).; A DLT will be defined as any grade 3 toxicity or greater according to CTCAE v5 considered at least possibly related to study treatment.; Safety will be defined as a  33% treatment-related DLT rate related to vaccination alone or in combination with retifanlimab by the end of the DLT observation period for a given cohort.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through completion of DLT observation period for all enrolled subjects (estimated to be up to 12 months and 87 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IA ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ia">Existing Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Now recruiting; Primary Completion Date moved earlier by 229 days</strong></td>
    <td>RZV Vaccine in HIV</td>
    <td>Calmy Alexandra</td>
<td><p>Phase 4</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_87">Study Arms</button></td>
    <td>Recombinant Zoster Vaccine</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05575830" target="_blank">NCT05575830</a></td><td><select class="form-select" id="select_form_94" name="NCT05575830"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 369 days</strong></td>
    <td>Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma</td>
    <td>Icahn School of Medicine at Mount Sinai</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_88">Study Arms</button></td>
    <td><p>Pembrolizumab; Flt3L; Radiation; Poly ICLC</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_546">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03789097" target="_blank">NCT03789097</a></td><td><select class="form-select" id="select_form_95" name="NCT03789097"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days; Start Date pushed later by 242 days</strong></td>
    <td>Newly-diagnosed glioblastoma</td>
    <td>Grupo Espaol de Investigacin en Neurooncologa</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_89">Study Arms</button></td>
    <td><p>TN-TC11G; Temozolomide Oral Product; Radiotherapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_546">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03529448" target="_blank">NCT03529448</a></td><td><select class="form-select" id="select_form_96" name="NCT03529448"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 151 days</strong></td>
    <td>Immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT)</td>
    <td>Yale University</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_90">Study Arms</button></td>
    <td>COVID19 vaccine</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05286242" target="_blank">NCT05286242</a></td><td><select class="form-select" id="select_form_97" name="NCT05286242"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 761 days; Primary Completion Date pushed later by 731 days</strong></td>
    <td>Highly Sensitized Prospective Kidney Transplant</td>
    <td>National Institute of Allergy and Infectious Diseases (NIAID)</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_91">Study Arms</button></td>
    <td><p>daratumumab; belatacept; Bone marrow aspiration</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_547">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04827979" target="_blank">NCT04827979</a></td><td><select class="form-select" id="select_form_98" name="NCT04827979"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 1622 days; Primary Completion Date pushed later by 1257 days</strong></td>
    <td>Relapsed/refractory B-cell lymphoma primary central nervous system lymphoma and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)</td>
    <td>UNC Lineberger Comprehensive Cancer Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_92">Study Arms</button></td>
    <td><p>iC9-CAR19 T cells; Bendamustine; Fludarabine; AP1903; Cyclophosphamide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_547">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03696784" target="_blank">NCT03696784</a></td><td><select class="form-select" id="select_form_99" name="NCT03696784"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo9" class="accordion-toggle">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_87" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Recombinant Zoster Vaccine</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Recombinant Zoster Vaccine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Geometric mean titer (GMT) of gE-specific total IgG</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>gE-specific total IgG titers is determined by gE-specific ELISA from sera samples</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 90</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_88" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Vaccination with Flt3L Radiation and Poly ICLC combined with Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab; Drug: Poly ICLC; Radiation: Radiation; Drug: Flt3L</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Limiting Toxicity (DLT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DLTs recorded and graded according to NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 4.03 within DLT evaluation window of 63 days (end of cycle 1 of pembrolizumab) from initiation of in situ vaccine.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>63 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_89" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>During Phase Ib Four to seven weeks after surgical diagnosis concurrent with radiotherapy (STUPP)||+ temozolomide (75mg/m2/day for 42 days) +TN-TC11G will be evaluated. During radiation therapy temozolomide and TN-TC11G will be administered. This last as the dose that have been selected previously based on dose-titration period. Patient specific dose will remain until progresion of disease unacceptable toxicity non-compliance consent withdrawal up to 2 years.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Temozolomide Oral Product; Radiation: Radiotherapy; Drug: TN-TC11G</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>THC-CBD Maximum tolerated dose|Incidence of Treatment-Emergent Adverse Events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>After intra-patient dose escalation period recommended dose of Glasdegib administeres with temozolamide during and after RT.; Type and number or adverse events reported during THC-CBD treatment based on the CTCAE reference criteria.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 months; 9 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_90" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Healthy controls Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.|Disease controls (individuals with a qualifying autoimmune condition but not treated with any immunomodulator).||Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.|Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with B-cell depleting anti-CD20 monoclonal antibodies.||Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.|Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with a non-CD20 monoclonal antibody immunomodulator to treat their disease.||Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: COVID19 vaccine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Change in coronavirus disease 19 (COVID19) antibody titers over time|Change in severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) specific T-cell activation over time</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Flow cytometry characterizing immunophenotype of SARS-CoV2 specific T cells; COVID 19 spike and neutralizing antibody titers will be monitored serially</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline 2 weeks post vaccine 1 pre-vaccine 2 1 week post vaccine 2 6 months post vaccine 2; pre- and 2 week post any additional vaccines</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_91" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:||Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.|Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8 10 12 and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit and will not be modified during the course of therapy unless there is a change in body weight of greater than 10%.|The enrollment of ten additional subjects is dependent on the results in Cohort 1.||Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:||Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.||Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8 10 12 and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit and will not be modified during the course of therapy unless there is a change in body weight of greater than 10%.||May be modified based on the safety and efficacy analysis of Cohort 1.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Bone marrow aspiration; Biological: daratumumab; Biological: belatacept</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Proportion of subjects who have not met a subject stopping rule and remain free of all of the safety events listed in the outcome description through 26 weeks after starting treatment or until receiving a transplant whichever occurs earlier|Proportion of subjects who meet any one of the pre-specified events detailed in the outcome description: from Baseline up to Week 26</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The study site will grade the severity of adverse events experienced by the study subjects according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (Published November 27 2017).; Proportion of subjects who meet any one of the following compared to Baseline (Visit 0):; Kidney transplant with a previously incompatible donor within 26 weeks after starting treatment without graft loss due to acute antibody mediated rejection occurring within the first four weeks post-transplant and caused by an anamnestic response.; Proportion of subjects who have not met a subject stopping rule and remain free of all of the following through 26 weeks after starting treatment or until receiving a transplant whichever occurs earlier:; 50% or greater reduction in the mean fluorescence intensity (MFI) of at least three HLA antibodies at Visit 12 (16 weeks 7 days after starting treatment); and/or; Any malignancy; Grade 3 or higher infections; Elimination of one human leukocyte antigen (HLA) antibody at Visit 12 (16 weeks 7 days after starting treatment);; Grade 3 or higher infusion reaction</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline (Visit 0) up to 26 weeks post treatment initiation; Baseline up to 26 weeks post treatment initiation</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_92" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The safety of iC9-CAR19 cells will be investigated using the 3+3 design. Dose level (DL) Dose (#transduced cells/kg)||-1 1 x 10^5||1 x 10^6|2 x 10^6 DL1 will enroll 3 subjects. If no toxicity within 4 weeks then DL 2 will enroll 3 subjects. If toxicity in 1/3 subjects in DL 1 3 more subjects will be enrolled. If DL 1 is not tolerable a de-escalation to DL -1 will enroll 3 subjects. If 3 subjects at the higher dose do not have DLTs more will be enrolled at that dose to get more information about toxicity.||Lymphodepleting chemotherapy of IV bendamustine 70 mg/m2 and IV fludarabine 30 mg/m2/day for 3 consecutive days will be given within 2-14 days prior to cell infusion.||AP1903 (0.4 mg/kg) a dimerizing agent to engage and activate the caspase 9 safety switch to trigger iC9-CAR19 T cell death by apoptosis will be given to subjects who develop severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).|After the tolerable cell dose (TCD) has been determined in adults up to 18 additional subjects may be enrolled in an expansion cohort at the TCD. A TCD is defined as the dose at which approximately 0.20 of subjects experience dose limiting toxicity (0 - 1 out of 6 subjects).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cyclophosphamide; Biological: iC9-CAR19 T cells; Drug: AP1903; Drug: Fludarabine; Drug: Bendamustine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with adverse events as a measure of safety and tolerability of iC9-CAR19 T cells</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Toxicity will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE version 5.0). Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. ICANS symptoms will be graded per ASBMT ICANS Consensus Grading for Adults (scale from 1-mild to 4-critical) and cytokine release syndrome (CRS) symptoms will be graded according to ASBMT CRS Consensus Grading (a scale from 1-mild to 5-death).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>4 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## FDA APPROVALS ######## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="approvals">Drug Approvals/Applications</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
<tr data-toggle="collapse" data-target="#demo10" class="accordion-toggle">    <td>Bayer Orion</td>
    <td>Darolutamide receives approval for additional prostate cancer indication in Japan</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02799602" target="_blank">ARASENS (NCT02799602)</a></td><td><select class="form-select" id="select_form_100" name="NCT02799602"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_503" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['100MG/4ML (25MG/ML)' '1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_504" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['500MG/10ML (50MG/ML)' '120MG/2.4ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_507" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>bevacizumab</td>
          <td>Avastin</td>
          <td>Genentech Inc.</td>
          <td>2/26/2004</td>
          <td>Intravenous</td>
          <td>['100MG/4ML (25MG/ML)' '400MG/16ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_508" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>LORLATINIB</td>
          <td>LORBRENA</td>
          <td>PFIZER</td>
          <td>Nov 2 2018</td>
          <td>TABLET;ORAL</td>
          <td>['100MG' '25MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_509" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>CORDEN PHARMA</td>
          <td>Nov 10 1983</td>
          <td>INJECTABLE;INJECTION</td>
          <td>20MG/ML</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>STRIDES PHARMA</td>
          <td>Dec 30 1986</td>
          <td>CAPSULE;ORAL</td>
          <td>['50MG' '100MG']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['100MG/4ML (25MG/ML)' '50MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_510" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['100MG/4ML (25MG/ML)' '1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['5/18/2016' '3/8/2019']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_512" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>LURBINECTEDIN</td>
          <td>ZEPZELCA</td>
          <td>JAZZ</td>
          <td>Jun 15 2020</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>4MG/VIAL</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_513" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['5/18/2016' '3/8/2019']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['120MG/12ML' '100MG/10ML' '40MG/4ML' '240MG/24ML']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['100MG/4ML (25MG/ML)' '50MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_516" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['500MG/10ML (50MG/ML)' '120MG/2.4ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_517" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>OSIMERTINIB MESYLATE</td>
          <td>TAGRISSO</td>
          <td>ASTRAZENECA</td>
          <td>Nov 13 2015</td>
          <td>TABLET;ORAL</td>
          <td>['EQ 40MG BASE' 'EQ 80MG BASE']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_518" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_519" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '10MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCEFREZ</td>
          <td>SUN PHARM</td>
          <td>May 3 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/VIAL' '20MG/VIAL']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACCORD HLTHCARE</td>
          <td>['Apr 20 2012' 'Jun 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '80MG/2ML (40MG/ML)' '160MG/8ML (20MG/ML)' '20MG/0.5ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACTAVIS LLC</td>
          <td>['Sep 21 2015' 'Apr 12 2013']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '160MG/8ML (20MG/ML)' '140MG/7ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>APOTEX INC</td>
          <td>Jan 11 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/0.5ML (40MG/ML)' '80MG/2ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>HOSPIRA INC</td>
          <td>['Jun 23 2016' 'Jan 24 2017' 'Mar 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/8ML (10MG/ML)' '120MG/6ML (20MG/ML)' '20MG/ML (20MG/ML)' '80MG/4ML (20MG/ML)' '160MG/16ML (10MG/ML)' '20MG/2ML (10MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>PFIZER LABS</td>
          <td>Mar 13 2014</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['200MG/20ML (10MG/ML)' '80MG/8ML (10MG/ML)' '130MG/13ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SANDOZ</td>
          <td>Jun 29 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SHILPA</td>
          <td>Dec 22 2015</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SUN PHARM</td>
          <td>Jan 8 2019</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>TAXOTERE</td>
          <td>SANOFI AVENTIS US</td>
          <td>['May 14 1996' 'Aug 2 2010' 'Apr 13 2012' 'Aug 3 2010']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>CORDEN PHARMA</td>
          <td>Nov 10 1983</td>
          <td>INJECTABLE;INJECTION</td>
          <td>20MG/ML</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>STRIDES PHARMA</td>
          <td>Dec 30 1986</td>
          <td>CAPSULE;ORAL</td>
          <td>['50MG' '100MG']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['100MG/4ML (25MG/ML)' '1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_523" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['100MG/4ML (25MG/ML)' '50MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_524" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>CORDEN PHARMA</td>
          <td>Nov 10 1983</td>
          <td>INJECTABLE;INJECTION</td>
          <td>20MG/ML</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>STRIDES PHARMA</td>
          <td>Dec 30 1986</td>
          <td>CAPSULE;ORAL</td>
          <td>['50MG' '100MG']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['500MG/10ML (50MG/ML)' '120MG/2.4ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_526" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>BRIGATINIB</td>
          <td>ALUNBRIG</td>
          <td>TAKEDA PHARMS USA</td>
          <td>['Oct 2 2017' 'Apr 28 2017']</td>
          <td>TABLET;ORAL</td>
          <td>['180MG' '30MG' '90MG']</td>
            </tr>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['500MG/10ML (50MG/ML)' '120MG/2.4ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_527" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['100MG/4ML (25MG/ML)' '50MG']</td>
            </tr>
            <tr>
          <td>trastuzumab</td>
          <td>Herceptin</td>
          <td>Genentech Inc.</td>
          <td>['9/25/1998' '2/10/2017']</td>
          <td>Intravenous</td>
          <td>['420MG' '150MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_530" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>REGORAFENIB</td>
          <td>STIVARGA</td>
          <td>BAYER HLTHCARE</td>
          <td>Sep 27 2012</td>
          <td>TABLET;ORAL</td>
          <td>40MG</td>
            </tr>
            <tr>
          <td>avelumab</td>
          <td>Bavencio</td>
          <td>EMD Serono Inc.</td>
          <td>3/23/2017</td>
          <td>Intravenous</td>
          <td>200MG/10ML (20MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_532" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['200MG/40ML (5MG/ML)' '50MG/10ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['120MG/12ML' '100MG/10ML' '40MG/4ML' '240MG/24ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_534" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>FULVESTRANT</td>
          <td>FASLODEX</td>
          <td>ASTRAZENECA</td>
          <td>Apr 25 2002</td>
          <td>INJECTABLE;INTRAMUSCULAR</td>
          <td>50MG/ML</td>
            </tr>
            <tr>
          <td>FULVESTRANT</td>
          <td>FULVESTRANT</td>
          <td>FRESENIUS KABI USA</td>
          <td>May 20 2019</td>
          <td>SOLUTION;INTRAMUSCULAR</td>
          <td>250MG/5ML (50MG/ML)</td>
            </tr>
            <tr>
          <td>FULVESTRANT</td>
          <td>FULVESTRANT</td>
          <td>TEVA PHARMS USA INC</td>
          <td>Aug 19 2019</td>
          <td>SOLUTION;INTRAMUSCULAR</td>
          <td>250MG/5ML (50MG/ML)</td>
            </tr>
            <tr>
          <td>LETROZOLE</td>
          <td>FEMARA</td>
          <td>NOVARTIS PHARMS</td>
          <td>Jul 25 1997</td>
          <td>TABLET;ORAL</td>
          <td>2.5MG</td>
            </tr>
            <tr>
          <td>PALBOCICLIB</td>
          <td>IBRANCE</td>
          <td>PFIZER</td>
          <td>['Feb 3 2015' 'Nov 1 2019']</td>
          <td>['CAPSULE;ORAL' 'TABLET;ORAL']</td>
          <td>['100MG' '125MG' '75MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_535" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ABEMACICLIB</td>
          <td>VERZENIO</td>
          <td>ELI LILLY AND CO</td>
          <td>Sep 28 2017</td>
          <td>TABLET;ORAL</td>
          <td>['50MG' '100MG' '150MG' '200MG']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '10MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['100MG/4ML (25MG/ML)' '1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>cetuximab</td>
          <td>Erbitux</td>
          <td>Eli Lilly and Company</td>
          <td>['2/12/2004' '3/28/2007']</td>
          <td>Intravenous</td>
          <td>['200MG/100ML (2MG/ML)' '100MG/50ML (2MG/ML)']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['100MG/4ML (25MG/ML)' '50MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_536" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['120MG/12ML' '100MG/10ML' '40MG/4ML' '240MG/24ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_538" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['120MG/12ML' '100MG/10ML' '40MG/4ML' '240MG/24ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_539" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '10MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_540" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>LENVATINIB MESYLATE</td>
          <td>LENVIMA</td>
          <td>EISAI INC</td>
          <td>Feb 13 2015</td>
          <td>CAPSULE;ORAL</td>
          <td>['EQ 10MG BASE' 'EQ 4MG BASE']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['100MG/4ML (25MG/ML)' '50MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_543" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['200MG/40ML (5MG/ML)' '50MG/10ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['120MG/12ML' '100MG/10ML' '40MG/4ML' '240MG/24ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_546" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>TEMOZOLOMIDE</td>
          <td>TEMODAR</td>
          <td>MERCK SHARP DOHME</td>
          <td>['Feb 27 2009' 'Aug 11 1999' 'Oct 19 2006']</td>
          <td>['CAPSULE;ORAL' 'POWDER;INTRAVENOUS']</td>
          <td>['100MG/VIAL' '20MG' '100MG' '5MG' '140MG' '250MG' '180MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_547" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>EUGIA PHARMA SPECLTS</td>
          <td>Aug 25 2021</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/2.5ML (200MG/ML)' '1GM/5ML (200MG/ML)']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>HIKMA</td>
          <td>Sep 16 2013</td>
          <td>CAPSULE;ORAL</td>
          <td>['50MG' '25MG']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>INGENUS PHARMS LLC</td>
          <td>['Nov 19 2021' 'Jul 30 2020']</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/2.5ML (200MG/ML)' '1GM/5ML (200MG/ML)' '2GM/10ML (200MG/ML)']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYTOXAN</td>
          <td>BAXTER HLTHCARE</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['INJECTABLE;INJECTION' 'TABLET;ORAL']</td>
          <td>['50MG' '200MG/VIAL' '25MG' '100MG/VIAL']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYTOXAN (LYOPHILIZED)</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Aug 30 1982' 'Sep 24 1985' 'Approved Prior to Jan 1 1982' 'Dec 10 1985' 'Jan 4 1984']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['500MG/VIAL' '2GM/VIAL' '1GM/VIAL']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>LYOPHILIZED CYTOXAN</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Dec 10 1985' 'Dec 5 1985']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['200MG/VIAL' '100MG/VIAL']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<center><button type="submit" value="submit">Submit</button></center></div></form><br><p><strong> <em>Disclaimer: This weekly digest is a product created exclusively by Lexidyne LLC, in collaboration with Janssen. The intended purpose is to identify clinical phase assets with new data related to lung cancer, priority mechanisms of action, local/intratumoral delivery, and/or increased potency for acquisition & business development consideration. </em> </strong></p><p><em>Sources used include but are not limited to: PubMed, ClinicalTrials.gov, ASCO, AACR, NIH, EU Clinical Trials Register, European Pharmaceutical Review, FDA.gov, PRNewsWire, FiercePharma, and BioSpace. </em> </p><center><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSffyxD4xZGkc99oZTy9lF0xPdIaqUMfCVpI2lWJzBkH3uDEag/viewform" target="_blank">Subscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdaRqTScaPylLdbIIgAaWs3eYn3wMcF_qF408_-D9caWHAgLw/viewform" target="_blank">Unsubscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdSCfl2l2sV2jo-vFfym-VPpzyEs5M0cRRPY5TmBIZ-nR6gSQ/viewform" target="_blank">Feedback</a></div></center>
